Scientific Program

Day 1 October 02, 2017

09:15-09:45 Registrations

Conference Hall: Fleming's 9

conferenceseries.com 09:45-10:15 **Opening Ceremony**

Welcome Speech

10:15-10:45 **Michael Binder**
Medical Director Vienna Hospital Association, Austria

Keynote Forum

10:45-11:30 **Title: The use of multislice CT angiography in the surgical treatment of ruptured intracranial aneurysms**
Dionisio Figueiredo Lopes, Hospital de Urgencia Otavio Lage, Brazil

Networking and Refreshments Break 11:30-11:50 @ Foyer

11:50-12:35 **Title: Neuroinflammation: Prodrome of neurological and neurodegenerative diseases**
Antonio Scilimati, University of Bari, Italy

12:35-13:20 **Title: Pseudobulbar affect, cognitive dysfunction and depression in poorly controlled diabetes**
Hanan Sheikh Ibrahim, Cleveland Clinic Abu Dhabi, UAE

Lunch Break 13:20-14:10 @ Flemings Restaurant

Sessions: CNS Disorders | Neurosurgery
Session Chair: Dionisio Figueiredo Lopes, Hospital de Urgencia Otavio Lage, Brazil
Session Co-chair: Khin Bo Maung, Northern Lincolnshire and Goole NHS Foundation Trust, United Kingdom

Session Introduction

14:10-14:40 **Title: Challenges in awake craniotomy for intrinsic brain tumors in eloquent cortex**
Debabrata Mukhopadhyay, Kailash Group of Hospitals, India

14:40-15:10 **Title: Pyrethroid bifenthrin induces neuronal damage, cognitive impairment associated with oxidative damage in rat's hippocampus : Possible involvement of Nurr1/Nrf2 and nf-kb pathways**
Brahim Gargouri, University of Freiburg Medical School, Germany

15:10-15:40 **Title: Dementia in Mauritius- Starting an early dementia diagnosis clinic**
Ameenah Sorefan, Alzheimer Association, Mauritius

Session Discussion

Networking and Refreshments Break 15:40-16:00 @ Foyer

Sessions: Cognitive Neurology | Case Reports
Session Chair: Antonio Scilimati, University of Bari, Italy
Session Co-chair: Hanan Sheikh Ibrahim, Cleveland Clinic Abu Dhabi, UAE

Session Introduction

16:00-16:30 **Title: Reactive cuprizone-induced changes in neurons of central nervous system, behavioral reactions and its recovering after influence of leukemia inhibitory factor in mice of different ages**
Melnyk Nataliia O, O O Bogomolets National Medical University, Ukraine

16:30-17:00 **Title: Neuroprotective effect of exogenous melatonin on the noradrenergic neurons of adult male rats' locus coeruleus nucleus following REM sleep deprivation**
Seyed Behnamedin Jameie, Iran University of Medical Sciences, Iran

Panel Discussion

Day 2 October 03, 2017

Conference Hall: Fleming's 9

Keynote Forum

10:15-11:00
Title: Multiple sclerosis, corpus callosum & bedside test
Khin Bo Maung, Northern Lincolnshire and Goole NHS Foundation Trust, United Kingdom

Networking and Refreshments Break 11:00-11:20 @ Foyer

11:20-12:05
Title: Metabolism of myelin in health and pathology
Alessandro Morelli, University of Genoa, Italy

Sessions: Neurobiology of CNS | Clinical Trials in CNS

Session Chair: Khin Bo Maung, Northern Lincolnshire and Goole NHS Foundation Trust, United Kingdom
Session Co-Chair: Hanan Sheikh Ibrahim, Cleveland Clinic Abu Dhabi, UAE

Session Introduction

12:05-12:35
Title: Neuromyelitis optica: A case report
Abdel Wahhab O Gh, V N Karazin Kharkiv National University, Ukraine

12:35-13:05
Title: Effects of 660 nm low-level laser therapy on P2X3 expression of lumbar DRG of adult male rats with neuropathic pain
Seyed Behnamedin Jameie, Iran University of Medical Sciences, Iran

Session Discussion

Lunch Break 13:05-14:00 @ Flemings Restaurant

Poster Presentations 14:00-15:00

Poster Judge: Hanan Sheikh Ibrahim, Cleveland Clinic Abu Dhabi, UAE
Poster Judge: Dionisio Figueiredo Lopes, Hospital de Urgencia Otavio Lage, Brazil

P1
Title: Neuromyelitis optica: A case report
Delich Olena, V N Karazin Kharkiv National University, Ukraine

P2
Title: Protective effect of histidine on para-nonylphenol enhances 1-methyl-4-phenylpyridinium ion-induced hydroxyl free radical generation in rat striatum
Toshio Obata, Osaka Aoyama University, Japan

P3
Title: ARE-binding factors TTP and HUR reveal antagonistic relationships within glioma-related gene networks
Dmitryi Chistyakov, A N Belozersky Research Institute of Physico-Chemical Biology MSU, Russia

P4
Title: Astroglial cell cultures do not produce resolvin D1 in course of LPS-induced response
Dmitryi Chistyakov, A N Belozersky Research Institute of Physico-Chemical Biology MSU, Russia

P5
Title: Benzimidazoles as epigenetic regulators of PRC2 protein complex with dual action as anti-tumor and nerve regenerators: Synthesis and molecular modeling Study
Hoda Azmy, Mansoura University, Egypt

P6
Title: Aquatic physical activity alters plasmatic BDNF levels in individuals with Parkinson's disease
Silvia Da Silva, Centro Universitário Metodista-IPA, Brazil

P7
Title: Experiences of PTSD from traumatic incidents: A paradigm model from qualitative research
Yun Jung Choi, Chung-Ang University, South Korea

P8
Title: Glioblastoma multiforme: An advanced analysis of 153 patients and review of the literature
Mohammad Sadegh Nikdad, Tehran University of Medical Sciences, Iran

Awards & Closing Ceremony

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org Website: cns.conferenceseries.com

List of Open Access Journals

Agri, Food & Aqua

Advances in Crop Science and Technology	2329-8863
Advances in Dairy Research	2329-888X
Agrotechnology	2168-9881
Aquaculture Research & Development	2155-9546
Arabidopsis C. Elegans and Zebrafish	-
Biofertilizers & Biopesticides	2155-6202
Crop Research	2454-1761
Experimental Food Chemistry	-
Fisheries & Livestock Production	2332-2608
Fisheries and Aquaculture Journal	2150-3508
Fisheriessciences	1307-234X
Food & Industrial Microbiology	-
Food & Nutritional Disorders	2324-9323
Food Processing & Technology	2157-7110
Food: Microbiology, Safety & Hygiene	-
Forest Research	2168-9776
Horticulture	2376-0354
International Biodiversity, Bioprospecting and Development	2376-0214
Marine Science: Research & Development	2155-9910
Medicinal & Aromatic Plants	2167-0412
Nutrition & Food Sciences	2155-9600
Plant Pathology & Microbiology	2157-7471
Poultry, Fisheries & Wildlife Sciences	2375-446X
Probiotics & Health	2329-8901
Research & Reviews: Journal of Agriculture and Allied Sciences	2347-226X
Research & Reviews: Journal of Food and Dairy Technology	2321-6204
Rice Research	2375-4338
Traditional Medicine and Clinical Naturopathy (Homeopathy & Ayurvedic Medicine-2167-1206)	-

Business & Management

Accounting & Marketing	2168-9601
Arabian Journal of Business and Management Review	2223-5833
Business & Financial Affairs	2167-0234
Business & Hotel Management	2324-9129
Business and Economics Journal	2151-6219
Defense Studies & Resource Management	2324-9314
Entrepreneurship & Organization Management	2169-026X
Global Economics	2375-4389
Hotel & Business Management	2169-0286
International Journal of Accounting Research	-
International Journal of Economics and Management Science	2162-6359
Internet Banking & Commerce	1204-5357
Review of Public Administration and Management	2315-7844
Stock & Forex Trading	2168-9458
Tourism & Hospitality	2167-0269

Chemical Engineering

Advanced Chemical Engineering	2090-4568
Bioprocessing & Biotechniques	2155-9821
Chemical Engineering & Process Technology	2157-7048
Thermodynamics & Catalysis	2157-7544

Chemistry

Analytical & Bioanalytical Techniques	2155-9872
Analytical & Electrochemical Insights	-
Bioenergetics: Open Access	2167-7662
Chemical Informatics	-
Chemical Sciences Journal	2150-3494
Chromatography & Separation Techniques	2157-7064
Clinical & Medical Biochemistry: Open Access	-
Clinical Chemistry: Open Access	-
Environmental & Analytical Toxicology	2161-0525
Environmental Analytical Chemistry	-
Glycobiology	2168-958X
Herbal Medicine: Open Access	-
Immuno Chemistry: Open Access	-
Industrial Chemistry: Open Access	-
International Journal of Applied Biology and Pharmaceutical Technology	0976-4550
International Journal of Drug Development & Research	0975-9344
Mass Spectrometry: Open Access	-
Medicinal Chemistry	2161-0444
Modern Chemistry & Applications	2329-6798
Natural Products Chemistry & Research Journal	2329-6836
Neuro Chemistry: Open Access	-
Organic & Inorganic Chemistry	-
Organic Chemistry: Current Research	2161-0401
Pharmaceutical Analytical Chemistry: Open Access	-
Physical Chemistry & Biophysics	2161-0398
RROIJ: Medicinal Chemistry	-
Structural Chemsitry & Crystallography Communication	-
Trends in Green Chemistry	-
Vitamins & Minerals	2376-1318

Clinical

Ageing Science	2329-8847
Ancient Diseases & Preventive Remedies	2329-8731
Anesthesia & Clinical Research	2155-6148
Annals of Clinical and Laboratory Research	2386-5180
Arrhythmia: Open Access	-
Atherosclerosis: Open Access	-
Cell Biology: Research & Therapy	2324-9293
Cellular & Molecular Pathology	-
Clinical & Experimental Cardiology	2155-9880
Clinical & Experimental Dermatology Research	2155-9554
Clinical & Experimental Nephrology	-
Clinical & Experimental Oncology	2324-9110
Clinical & Experimental Ophthalmology	2155-9570
Clinical & Experimental Orthopaedics	-
Clinical & Experimental Pathology	2161-0681
Clinical & Molecular Endocrinology	-
Clinical and Experimental Psychology	-
Clinical and Experimental Transplantation	-
Clinical Case Reports	2165-7920
Clinical Depression	-
Clinical Dermatology Research Journal	-
Clinical Diabetes & Practice	-
Clinical Nutrition & Dietetics	-
Clinical Oncology and Practice	-
Clinical Pediatrics	-
Clinical Pediatrics & Dermatology	-
Clinical Psychiatry	-
Clinical Research & Bioethics	2155-9627
Clinical Research On Foot & Ankle	2329-910X
Clinical Respiratory: Open Access	-
Clinical Toxicology	2161-0495
Clinical Trials	2167-0870
Clinics in Mother and Child Health	2090-7214
Cosmetology & Orofacial Surgery	-
Cosmetology & Trichology	-
Dermatitis	-
Diabetes Case Reports	-
Dialysis and Clinical Practice	-
Drug Intoxication & Detoxification : Novel Approaches	2327-4557
Dual Diagnosis: Open Access	-
Eye & Cataract Refractive Surgery	-
Forensic Toxicology & Pharmacology	2325-9841
Glaucoma: Open Access	-
HIV & Retro Virus	-
Immunooncology	-
Insights in Pediatric Cardiology	-

Intensive and Critical Care	-
International Journal of Anesthesiology & Pain Medicine	-
International Journal of Cardiovascular Research	2324-8602
International Journal of Digestive Diseases	-
International Journal of Ophthalmic Pathology	2324-8599
Interventional Cardiology: Open Access	-
JBR Journal of Clinical Diagnosis and Research	2376-0311
Optometry: Open Access	-
Phonetics & Audiology	-
Speech Pathology & Therapy	-
Stem Cell Research & Therapy	2157-7633
Toxicology: Open Access	-
Vasculitis	-

Earth & Environmental Sciences

Advances in Recycling	-
Astrobiology & Outreach	2332-2519
Biodiversity & Endangered Species	2332-2543
Biodiversity Management & Forestry	2327-4417
Bioremediation & Biodegradation	2155-6199
Biosafety	2167-0331
Climatology & Weather Forecasting	2332-2594
Coastal Zone Management	-
Earth Science & Climatic Change	2157-7617
Ecosystem & Ecography	2157-7625
Entomology, Ornithology & Herpetology	2161-0983
Expert Opinion On Environmental Biology	2325-9655
Fundamentals of Renewable Energy and Applications	2090-4541
Geography & Natural Disasters	2167-0587
Geoinformatics & Geostatistics: An Overview	2327-4581
Geology & Geosciences	2329-6577
Geophysics & Remote Sensing	2169-0049
Hydrogeology & Hydrologic Engineering	2325-9647
Hydrology: Current Research	2157-7587
Industrial Pollution Control	-
Innovative Energy Policies	2090-5009
International Journal of Evolution	2324-8548
International Journal of Waste Resources	2252-5211
Marine Biology & Oceanography	2324-8661
Oceanography: Open Access	2332-2632
Oil & Gas: Open Access	-
Petroleum & Environmental Engineering	2157-7463
Plant Physiology & Pathology	2329-955X
Pollution Effects & Control	2375-4397
Research & Reviews: Journal of Ecology and Environmental Sciences	-

EEE

Electrical & Electronic Systems	2332-0796
Electrical Engineering & Electronic Technology	2325-9833

Engineering

Advances in Automobile Engineering	2167-7670
Advances in Robotics & Automation	2168-9695
Aeronautics & Aerospace Engineering	2168-9792
Applied Bioinformatics & Computational Biology	2329-9533
Applied Mechanical Engineering	2168-9873
Architectural Engineering Technology	2168-9717
Automatic Control of Physiological State and Function	2090-5092
Biochips & Tissue Chips	2153-0777
Bioengineering & Biomedical Science	2155-9538
Biomusical Engineering	2090-2719
Biosensors & Bioelectronics	2155-6210
Biosensors Journal	2090-4967
Civil & Environmental Engineering	2165-784X
Computer Engineering & Information Technology	2324-9307
Computer Engineering and Information Technology	2324-9307
Defense Management	2167-0374
Fashion Technology & Textile Engineering	2329-9568
Global Journal of Technology and Optimization	2229-8711
Global Research in Computer Science	2229-371X
Industrial Engineering & Management	2169-0316
Information Technology & Software Engineering	2165-7866
International Journal of Advanced Research in Electrical, Electronics and Instrumentation Engineering	2278-8875
International Journal of Advancements in Technology	0976-4860
International Journal of Biomedical Data Mining	2090-4924
International Journal of Innovative Research in Computer and Communication Engineering	2278-1021
International Journal of Innovative Research in Science, Engineering and Technology	2319-8753
International Journal of Sensor Networks and Data Communications	2090-4886
International Journal of Swarm Intelligence and Evolutionary Computation	2090-4908
Irrigation & Drainage Systems Engineering	2168-9768
Lasers, Optics & Photonics	-
Lovotics	2090-9888
Membrane Science & Technology	2155-9589
Molecular Imaging & Dynamics	2155-9937
Nuclear Energy Science & Power Generation Technology	2325-9809
Research & Reviews: Journal of Engineering and Technology	2319-9873
Steel Structures & Construction	-
Telecommunications System & Management	2167-0919
Textile Science & Engineering	2165-8064

General Science

Computer Science & Systems Biology Journal	0974-7230
Ergonomics	2165-7556
Research and Development	-
International Journal of Advance Innovations, Thoughts & Ideas	2277-1891
Metrology	-
Research & Reviews: Journal of Botanical Sciences	2320-0189
Research & Reviews: Journal of Chemistry	2319-9849
Tomography	-

Genetics & Molecular Biology

Advanced Techniques in Biology & Medicine	2379-1764
Advancements in Genetic Engineering	2169-0111
Advances in Molecular Diagnostics	-
Biochemistry & Analytical Biochemistry	2161-1009
Biochemistry & Molecular Biology Journal	-
Biochemistry & Physiology	2329-9029
Biological Systems	2329-6577
Biotechnology & Biomaterials	2155-952X
Bipolar Disorder: Open Access	-
Cell & Developmental Biology	2168-9296
Cell Science & Therapy	2157-7013
Cell Signaling	-
Cellular & Molecular Medicine: Open Access	-
Chemical Biology & Therapeutics	-
Clinical Epigenetics	-
Cloning & Transgenesis	2168-9849
Current Synthetic and Systems Biology	2332-0737
Cytology & Histology	2157-7099
Down Syndrome & Chromosome Abnormalities	-
Electronic Journal of Biology	-
Enzyme Engineering	2329-6674
Fertilization: in Vitro	2375-4508
Fungal Genomics & Biology	2165-8056
Gene Technology	2329-6682
Genetic Syndromes & Gene Therapy	2157-7412
Hereditary Genetics: Current Research	2161-1041
Human Genetics & Embryology	2161-0436
Insights in Cell Science	-
Insights in Stem Cells	-
International Journal of Genomic Medicine	2332-0672
Metabolomics: Open Access	2153-0769
Metabonomics & Metabolites	2325-9736
Microbial & Biochemical Technology	1948-5948
Microbial Methods & Assays Open Access	-
Molecular and Genetic Medicine	1747-0862
Molecular Biology	2168-9547
Molecular Biomarkers & Diagnosis	2155-9929
Molecular Cloning & Genetic Recombination	2325-9787
Nanomedicine & Biotherapeutic Discovery	2155-983X
Next Generation: Sequencing & Applications	-
Phylogenetics & Evolutionary Biology	2329-9002

Physiobiochemical Metabolism	2324-8793
Plant Biochemistry & Physiology	2329-9029
Proteomics & Enzymology	-
Single Cell Biology	2168-9431
Tissue Science & Engineering	2157-7552
Transcriptomics: Open Access	2329-8936
Translational Biomedicine	2172-0479

Health Care

Diversity and Equality and Health and Care	2049-5471
Health Care: Current Reviews	2375-4273
Health Science Journal	1791-809X
Pregnancy & Child Health	2376-127X
Primary Health Care	2167-1079
Quality in Primary Care	1479-1072
Tropical Diseases & Public Health	2329-891X
Women'S Health, Issues & Care	2325-9795

Immunology

Advances in Antibiotics & Antibodies	-
Allergy & Therapy	2155-6121
Autoimmune Diseases: Open Access	-
Clinical & Cellular Immunology	2155-9899
Cytokine Biology	-
Immunobiology	-
Immunogenetics: Open Access	-
Immunome Research	1745-7580
Immunotherapy: Open Access	-
Infectious Diseases & Immunological Techniques	2325-9752
Inflammatory Bowel Diseases & Disorders	-
Innate Immunity & Immunological Disorders	-
Interdisciplinary Journal of Microinflammation	-
Lupus: Open Access	-
Molecular Immunology	-
Osteoarthritis	-
Reproductive Immunology	-
Rheumatology: Current Research	2161-1149
Sarcoidosis	-
Vaccines & Vaccination	2157-7560

Informatics

Data Mining in Genomics & Proteomics	2153-0602
Glycomics and Lipidomics	2153-0637
Health & Medical Informatics	2157-7420
Proteomics & Bioinformatics	0974-276X
Theoretical and Computational Science	2376-130X

Materials Science

Bioceramics Developments and Applications	2090-5025
Material Sciences & Engineering	2169-0022
Nano Research & Applications	-
Nanomaterials & Molecular Nanotechnology	2324-8777
Nanomedicine & Nanotechnology	2157-7439
Plastic & Polymer Sciences	-
Powder Metallurgy & Mining	2168-9806
Research & Reviews: Journal of Material Sciences	2321-6212

Mathematics

Applied & Computational Mathematics	2168-9679
Biometrics & Biostatistics	2155-6180
Generalized Lie Theory and Applications	1736-4337
Physical Mathematics	2090-0902
Research & Reviews: Journal of Statistics and Mathematical Sciences	-

Medical

Abnormal and Behavioural Psychology	-
Acta Psychopathologica	-
Acta Rheumatologica	-
Addictive Behaviors , Therapy & Rehabilitation	2324-9005
Adenocarcinoma	-
Advances in Cancer Prevention	-
Advances in Genetic Engineering & Biotechnology	-
Advances in Weight Loss Management & Medical Devices	-
Aerobics & Fitness	-
Aesthetic & Reconstructive Surgery	-
Aids & Clinical Research	2155-6113
Air and Water Borne Diseases	2167-7719
Alternative & Integrative Medicine	2327-5162
Analgesia & Resuscitation : Current Research	2324-903X
Anaplastology	2161-1173
Anatomy & Physiology: Current Research	2161-0940
Andrology & Gynecology: Current Research	2327-4360
Andrology	2167-0250
Angiology: Open Access	2329-9495
Annals of Behavioural Science	-
Applied and Rehabilitation Psychology: Open Access	-
Archives in Cancer Research	2254-6081
Archives of Medicine	1989-5216
Archives of Surgical Oncology	-
Archivos De Medicina	1698-9465
Arthritis	2167-7921
Asthma and Bronchitis	-
Athletic Enhancement	2324-9080
Autacoids & Hormones	2161-0479
Biology and Medicine	0974-8369
Biomedical Engineering & Medical Devices	-
Biomedical Sciences	2254-609X
Bioterrorism & Biodefense	2157-2526
Blood	-
Blood & Lymph	2165-7831
Blood Disorders & Transfusion	2155-9864
Blood Pressure: Open Access	-
Bone Marrow Research	2329-8820
Bone Reports & Recommendations	-
Brain Tumors	-
Breast Cancer: Current Research	-
Cancer Biomarkers	-
Cancer Clinical Trials	-
Cancer Diagnosis	-
Cancer Medicine & Anticancer Drugs	-
Cancer Science & Therapy	1948-5956
Cancer Surgery	-
Carcinogenesis & Mutagenesis	2157-2518
Cardiovascular Diseases & Diagnosis	2329-9517
Cardiovascular Pathology: Open Access	-
Celiac Disease: Open Access	-
Cervical Cancer: Open Access	-
Chemotherapy	2167-7700
Chest Diseases	-
Childhood & Developmental Disorders	-
Childhood Obesity	-
Chronic Obstructive Pulmonary Disease: Open Access	-
Colorectal Cancer: Open Access	-
Communication Disorders, Deaf Studies & Hearing Aids	2375-4427
Community Medicine & Health Education	2161-0711
Complex Diseases and Treatment	-
Contraceptive Studies	-
Critical Care Obstetrics & Gynecology	-
Current Trends in Gynecologic Oncology	-
Dental Health: Current Research	-
Dental Implants and Dentures: Open Access	-
Dentistry	2161-1122
Depression and Anxiety	2167-1044
Dermatology Case Reports	-
Diabetes & Metabolism	2155-6156
Diabetes Medication and Care	-
Diabetic Complications and Medicine	-
Drug Abuse	-
Emergency Medicine	2165-7548
Endocrinology & Diabetes Research	-
Endocrinology & Metabolic Syndrome	2161-1017
Epidemiology: Open Access	2161-1165
Evidence based Medicine and Practice	-
Family Medicine & Medical Science Research	2327-4972
Forensic Biomechanics	2090-2697
Forensic Medicine	-

Forensic Nursing: Open Access	-
Forensic Odontology	-
Forensic Psychology	-
Forensic Research	2157-7145
Gastrointestinal & Digestive System	2161-069x
Gastrointestinal Cancer and Stromal Tumors	-
General Medicine	2327-5146
General Practice	2329-9126
Genetic Disorders & Genetic Reports	2327-5790
Genital System & Disorders	2325-9728
Geriatric Psychiatry	-
Gerontology & Geriatric Research	2167-7182
Gynecology & Obstetrics	2161-0932
Gynecology & Obstetrics- Case Report	-
Haematology & Thromboembolic Diseases	2329-8790
Hair: Therapy & Transplantation	2167-0951
Head and Neck Cancer Research	-
Health & Medical Economics	-
Health Care Communications	-
Health Economics & Outcome Research: Open Access	-
Health Education Research & Development (Biosafety & Health Education: Open Access-2332-0893)	-
Health Systems and Policy Research	2254-9137
Heart Transplant and Surgery	-
Heavy Metal & Chelation Therapy	-
Hepatology and Gastrointestinal Disorders	-
Hospital & Medical Management	-
Hypertension- Open Access	2167-1095
Hypo & Hyperglycemia	2327-4700
Imaging and Interventional Radiology	-
Medical Implants & Surgery	-
Informatics and Data Mining	-
Insights in Biomedicine	-
Insights in Medical Physics	-
Integrative Oncology	2329-6771
Internal Medicine	2165-8048
International Journal of Clinical & Medical Imaging	2376-0249
International Journal of Collaborative Research on Internal Medicine & Public Health	-
International Journal of Emergency Mental Health and Human Resilience	1522-4821
International Journal of Mental Health & Psychiatry	2327-4654
International Journal of Pediatric Neurosciences	-
International Journal of Physical Medicine & Rehabilitation	2329-9096
International Journal of Public Health and Safety	-
International Journal of School and Cognitive Psychology	-
Interventional Pediatrics	-
Invasive Cardiology Future Medicine	-
JBR Journal of Interdisciplinary Medicine and Dental Sciences	2376-032X
Kidney	-
Kidney Transplant	-
La Prensa Medica	0032-745X
Laser Surgery and Therapy	-
Leukemia	2329-6917
Liposuction	-
Liver	2167-0889
Liver: Disease & Transplantation	2325-9612
Lung Cancer Diagnosis & Treatment	-
Lung Diseases & Treatment	-
Malaria Control & Elimination	2090-2778
Maternal and Pediatric Nutrition	-
Medical & Surgical Pathology	-
Medical & Surgical Urology	2168-9857
Medical and Clinical Reviews	-
Medical Case Reports	-
Medical Diagnostic Methods	2168-9784
Medical Toxicology and Clinical Forensic Medicine	-
Melanoma and Skin Diseases	-
Mental Health in Family Medicine	2327-4972
Mental Illness and Treatment	-
Metabolic Syndrome	2167-0943
Molecular & Medical Histology	-
Molecular Medicine & Therapeutics	2324-8769
Neonatal Biology	2167-0897
Neonatal Studies	-
Neonatal Medicine	-
Neoplasm	-
Nephrology & Therapeutics	2161-0959
Neurobiotechnology	-
Neuroinfectious Diseases	2314-7326
Neurooncology: Open Access	-
Neurosurgery & Cardiac Surgery	-
Novel Physiotherapies	2165-7025
Nuclear Medicine & Radiation Therapy	2155-9619
Nutritional Disorders & Therapy	2161-0509
Obesity & Eating Disorders	-
Obesity & Weight Loss Therapy	2165-7904
Occupational Medicine Health Affairs	2329-6879
Omics Journal of Radiology	2167-7964
Oncology & Cancer Case Reports	-
Oncology Translational Research	-
Oral Health and Dental Management	2247-2452
Oral Health Case Reports	-
Oral Hygiene & Health	2332-0702
Orthodontics & Endodontics	-
Orthopedic & Muscular System: Current Research	2161-0533
Orthopedic Oncology	-
Osteoporosis & Physical Activity	2329-9509
Otolaryngology:Open Access	2161-119X
Otology & Rhinology	2324-8785
Pain & Relief	2167-0846
Pain Management & Medicine	-
Palliative Care & Medicine	2165-7386
Pancreatic Disorders & Therapy	2165-7092
Pediatric Care	-
Pediatric Dental Care	-
Pediatric Emergency Care and Medicine- Open Access	-
Pediatric Nephrology Practice	-
Pediatric Neurology and Medicine	-
Pediatric Nursing: Open Access	-
Pediatric Oncology: Open Access	-
Pediatric Physiotherapy	-
Pediatric Psychology and Psychiatry	-
Pediatrics & Therapeutics	2161-0665
Periodontics and Prosthodontics: Open Access	-
Pigmentary Disorders	2376-0427
Prevention Infection Control: Open Access	-
Preventive Medicine	-
Primary & Acquired Immunodeficiency Research	2324-853X
Prostate Cancer	-
Psoriasis & Rosacea Open Access	-
Psychiatry	2378-5756
Psychological Abnormalities in Children	2329-9525
Psychology & Psychotherapy	2161-0487
Pulmonary & Respiratory Medicine	2161-105x
Rare Disorders & Diseases	-
Regenerative Medicine	2325-9620
Reproductive Endocrinology & Infertility	-
Reproductive System & Sexual Disorders	2161-038x
Research & Reviews: Journal of Dental Sciences	2320-7949
Research & Reviews: Journal of Medical and Health Sciences	2319-9865
Research Journal of Biology	2322-0066
Sleep Disorders & Therapy	2167-0277
Sleep Disorders : Treatment & Care	2325-9639
Spine	2165-7939
Spine & Neurosurgery	2325-9701
Spine Research	-
Sports Medicine & Doping Studies	2161-0673
Sports Nutrition and Therapy	-
Steroids & Hormonal Science	2157-7536
Stroke Research & Therapy	-
Journal of Surgery [Jurnalul de Chirurgie]	1584-9341
Surgery: Current Research	2161-1076
The Headache Journal	-
The International Journal of Apitherapy	-
The Pancreas	1590-8577
Therapeutic Care and Physical Rehabilitation	-

Thrombosis and Circulation	-
Thyroid Disorders & Therapy	2167-7948
Translational Medicine	2161-1025
Transplant Reports : Open Access	-
Transplantation Technologies & Research	2161-0991
Trauma & Acute Care	-
Trauma & Treatment	2167-1222
Traumatic Stress Disorders & Treatment	2324-8947
Tropical Medicine & Surgery	2329-9088
Tumor Diagnostics and Reports	-
Universal Surgery	2254-6758
Vascular Medicine & Surgery	2329-6925
Vitiligo & Dermatomyositis	-
Voice Medicine & Surgery	-
Women's Health Care	2167-0420
Wound Medicine and Tissue Repair	-
Yoga & Physical Therapy	2157-7595

Microbiology

Advances in Influenza Research	-
Antimicrobial Agents	-
Antivirals & Antiretrovirals	1948-5964
Applied Microbiology: Open Access	-
Archives of Clinical Microbiology	1989-8436
Bacteriology and Parasitology	2155-9597
Clinical Infectious Diseases & Practice	-
Clinical Microbiology: Open Access	2327-5073
Colitis & Diverticulitis	-
Emerging Infectious Diseases	-
Fermentation Technology	2167-7972
Fibromyalgia: Open Access	-
Forensic Pathology	-
Hepatitis	-
Human Papillomavirus	-
Infectious Diseases and Diagnosis	-
Infectious Diseases and Therapy	2332-0877
Medical Microbiology & Diagnosis	2161-0703
Medical Mycology: Open Access	-
Meningitis	-
Mycobacterial Diseases	2161-1068
Pediatric Infectious Diseases: Open Access	-
Research & Reviews: Journal of Microbiology and Biotechnology	2320-3528
Research & Reviews: Journal of Inflammation	-
Research & Reviews: Journal of Pathology & Epidemiology	-
Virology & Mycology	2161-0517

Neuroscience

Addiction Research & Therapy	2155-6105
Alzheimers Disease & Parkinsonism	2161-0460
Autism-Open Access	2165-7890
Brain Disorders & Therapy	2168-975X
Child & Adolescent Behavior	2375-4494
Clinical & Experimental Neuroimmunology	-
Dementia & Mental Health	-
Epilepsy Journal	-
Insights in Clinical Neurology	-
International Journal of Neurorehabilitation	2376-0281
Multiple Sclerosis	2376-0389
Neurological Disorders	2329-6895
Neurology & Neurophysiology	2155-9562
Neurology and Neuroscience	2171-6625
Neuropsychiatry	-
Neuroscience & Clinical Research	-
Schizophrenia Journal	-

Health Care & Nursing

Advanced Practices in Nursing	-
Community & Public Health Nursing	-
Nursing & Care	2167-1168
Nursing & Clinical Research	-
Patient Care	-
Perioperative & Critical Intensive Care Nursing	-
Research & Reviews: Journal of Nursing and Health Sciences	-

Pharmaceutical Sciences

Advances in Pharmacoepidemiology & Drug Safety	2167-1052
Alcoholism & Drug Dependence	2329-6488
Bioanalysis & Biomedicine	1948-593X
Biochemistry & Pharmacology: Open Access Journal	2167-0501
Bioequivalence & Bioavailability	0975-0851
Biomarkers in Drug Development	2327-4441
Biomarkers Journal	-
Biomolecular Research & Therapeutics	2167-7956
Cardiovascular Pharmacology: Open Access	2329-6607
Clinical & Experimental Pharmacology	2161-1459
Clinical Pharmacology and Biopharmaceutics	2167-065X
Current Trends in Nutraceuticals	-
Developing Drugs	2329-6631
Diagnostic Techniques & Biomedical Analysis	-
Drug Designing: Open Access	2169-0138
Drug Metabolism & Toxicology	2157-7609
in Silico & in Vitro Pharmacology	-
Molecular Enzymology and Drug Targets	-
Molecular Pharmaceutics & Organic Process Research	2329-9053
Pharmaceutica Analytica Acta	2153-2435
Pharmaceutical Care & Health Systems	2376-0419
Pharmaceutical Microbiology	-
Pharmaceutical Regulatory Affairs: Open Access	2167-7689
Pharmaceutical Sciences & Emerging Drugs	-
Pharmaceutics & Drug Delivery Research	2325-9604
Pharmacoeconomics: Open Access	-
Pharmacogenomics and Pharmacoproteomics	2153-0645
Pharmacognosy & Natural Products	-
Pharmacokinetics & Experimental Therapeutics	-
Pharmacological Reports	-
Pharmacovigilance	2329-6887
Research & Reviews: Journal of Hospital and Clinical Pharmacy	-
Research & Reviews: Journal of Pharmaceutical Analysis	2320-0812
Research & Reviews: Journal of Pharmaceutical Quality Assurance	-
Research & Reviews: Journal of Pharmaceutics and Nanotechnology	2347-7857
Research & Reviews: Journal of Pharmacognosy and Phytochemistry	2321-6182
Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences	2320-1215
Virology & Antiviral Research	2324-8955

Physics

Astrophysics & Aerospace Technology	2329-6542
Research & Reviews: Journal of Pure and Applied Physics	2320-2459
Vortex Science and Technology	2090-8369

Social & Political Sciences

Anthropology	2332-0915
Arts and Social Sciences Journal	2151-6200
Civil & Legal Sciences	2169-0170
Forensic Anthropology	-
Global Media Journal	1550-7521
Intellectual Property Rights: Open Access	2375-4516
Mass Communication & Journalism	2165-7912
Political Science & Public Affairs	2332-0761
Research & Reviews: Journal of Educational Studies	-
Research & Reviews: Journal of Social Sciences	-
Socialomics	2167-0358
Sociology & Criminology	2375-4435

Veterinary Sciences

Animal Nutrition	-
Primatology	2167-6801
Research & Reviews: Journal of Veterinary Sciences	-
Research & Reviews: Journal of Zoological Sciences	2321-6190
Veterinary Science & Medical Diagnosis	2325-9590
Veterinary Science & Technology	2157-7579

Impact Factors* (IF)

Journal Name	Pubmed Short Name	Impact Factor
Biological Systems: Open Access	Biol Syst Open Access	0.76
Journal of Biotechnology & Biomaterials	J Biotechnol Biomater	1.94
Journal of Psychology & Psychotherapy	J Psychol Psychother	1.3
Advanced Techniques in Biology & Medicine	Adv Tech Biol Med	1.08
AIDS & Clinical Research	J AIDS Clin Res	2.7
Autism Open Access	Autism Open Access	3.52
Biochemistry & Physiology: Open Access	Biochem Physiol	1.03
Diversity Equality in Health & Care	Divers Equal Health Care	2.49
Drug Designing: Open Access	Drug Des	6
Fungal Genomics & Biology	Fungal Genom Biol	1.15
International Journal of Genomic Medicine	Int J Genomic Med	0.67
Journal of Addiction Research & Therapy	J Addict Res Ther	2.86
Journal of Alzheimers Disease & Parkinsonism	J Alzheimers Dis Parkinsonism	1.18
Journal of Fertilization: In Vitro	JFIV Reprod Med Genet	1
Journal of Genetic Syndromes & Gene therapy	J Genet Syndr Gene Ther	2.34
Journal of Microbial & Biochemical Technology	J Microb Biochem Technol	2.5
Journal of Nursing & Care	J Nurs Care	1.6
Journal of Osteoporosis and Physical Activity	J Osteopor Phys Act	0.66
Journal of Yoga & Physical Therapy	J Yoga Phys Ther	1.17
Molecular Biology	Mol Biol	1.85
Neurology & Neurophysiology	J Neurol Neurophysiol	0.77
Primary health care	Prim Health Care	1
Quality in Primary Care	Qual Prim Care	3.88
Tissue Science & Engineering	J Tissue Sci Eng	2.72
Biochemistry & Analytical Biochemistry	Biochem Anal Biochem	2.6
Molecular and Genetic Medicine	J Mol Genet Med	2.89
Advancements in Genetic Engineering	Adv Genet Eng	1
Enzyme Engineering	Enz Eng	2.3
Depression and Anxiety	J Depress Anxiety	1
Human Genetics & Embryology	Human Genet Embryol	1.2
Current Synthetic and Systems Biology	Curr Synthetic Sys Biol	0.8
Hereditary Genetics: Current Research	Hereditary Genet	1.2
International Journal of Emergency Mental Health and Human Resilience	Int J Emerg Ment Health	6.5
Spine	J Spine	1.9
Cloning & Transgenesis	Clon Transgen	1.5
Journal of Medical Microbiology & Diagnosis	J Med Microb Diagn	1.9
Biosensors Journal	Biosens J	0.33
Defense Management	J Def Manag	0.5
Review of Public Administration and Management	Review Pub Administration Manag	0.2
Single cell biology	Single Cell Biol	1
Gerontology & Geriatric Research	J Gerontol Geriatr Res	1
Neuroinfectious Diseases	J Neuroinfect Dis	2.4
Cell Science & Therapy	J Cell Sci Ther	1.37
Molecular Biomarkers & Diagnosis	J Mol Biomark Diagn	2.1
Brain Disorders & Therapy	Brain Disord Ther	1.6
Clinical Case Reports	J Clin Case Rep	1.2
Gene Technology	Gene Technol	0.83
Socialomics	J Socialomics	2.3
Journal of Trauma and Treatment	J Trauma Treat	0.6
Translational Biomedicine	Transl Biomed	1.06
Journal of Neurology and Neuroscience	J Neurol Neurosci	0.88
Research & Reviews: Journal of Botanical Sciences	J Bot Sci	0.33
Journal of Psychiatry	J Psychiatry	2.32
Anaplastology	Anaplastology	0.73
Tropical Medicine & Surgery	Trop Med Surg	0.4
Orthopedic & Muscular System: Current Research	Orthop Muscular Syst	0.32
Pediatrics & Therapeutics	Pediat Therapeut	1.32
Sports Medicine & Doping Studies	J Sports Med Doping Stud	1.45
Journal of Oral Hygiene & Health	J Oral Hyg Health	0.52
Emergency Medicine	Emerg Med (Los Angel)	0.875
Journal of Transplantation Technologies & Research	J Transplant Technol Res	1.39
Journal of Hypertension: Open Access	J Hypertens (Los Angel)	0.92
International Journal of Waste Resources	Int J Waste Resour	1.95
Surgery: Current research	Surgery Curr Re	0.587
Oral Health and Dental Management	Oral Health Dent Manag	1.23
International Journal of Advancement technology	Int J Adv Tech	5.08
Translational Medicine	Transl Med (Sunnyvale)	1.312
Air and Water Borne Diseases	Air Water Borne Diseases	0.6
Journal of Coastal Zone Management	J Coast Zone Manag	0.54
Biology and Medicine	Biol Med (Aligarh)	3.07
Journal of Bioterrorism and Biodefense	J Bioterror Biodef	0.38
Journal of Tropical Diseases & Public Health	J Trop Dis	0.83
Journal of Surgery	Journal of Surgery [Jurnalul de chirurgie]	0.08
Nephrology & Therapeutics	J Nephrol Ther	0.318
Journal of Fundamentals of Renewable Energy and Applications	J Fundam Renewable Energy Appl	1.41
Advances in Pharmacoepidemiology & Drug Safety	Adv Pharmacoepidemiol Drug Saf	1.37
Bioanalysis & Biomedicine	J Bioanal Biomed	1.67
Biochemistry & Pharmacology: Open Access	Biochem Pharmacol (Los Angel)	2.09
Bioequivalence & Bioavailability	J Bioequiv Availab	1.88
Biomolecular Research & Therapeutics	J Biomol Res Ther	1.67
Cardiovascular Pharmacology: Open Access	Cardiol Pharmacol	1.77
Clinical & Experimental Pharmacology	Clin Exp Pharmacol	1.83
Clinical Pharmacology & Biopharmaceutics	Clin Pharmacol Biopharm	1.69
Data Mining in Genomics & Proteomics	J Data Mining Genomics Proteomics	2
Drug Metabolism & Toxicology	J Drug Metab Toxicol	1.37
Ergonomics	J Ergonomics	1.38
Glycomics & Lipidomics	J Glycomics Lipidomics	1.82
Health & Medical Informatics	J Health Med Inform	1.98
Metabolomics: Open Access	Metabolomics (Los Angel)	3.03
Nanomedicine & Biotherapeutic Discovery	J Nanomedine Biotherapeutic Discov	2.69
OMICS Journal of Radiology	OMICS J Radiol	0.54
Pharmaceutica Analytica Acta	Pharm Anal Acta	1.83
Pharmaceutical Regulatory Affairs: Open Access	Pharm Regul Aff	1.88
Pharmacogenomics & Pharmacoproteomics	J Pharmacogenomics Pharmacoproteomics	1.69
Pharmacovigilance	J Pharmacovigil	2.65
Phylogenetics & Evolutionary Biology	J Phylogenetics Evol Biol	2.76
Proteomics & Bioinformatics	J Proteomics Bioinform	2.55
Advances in Automobile Engineering	Adv Automob Eng	1.750
Advances in Robotics & Automation	Adv Robot Autom	0.813
Arts and Social Sciences Journal	Arts Social Sci J	1.231
Bioceramics Developments and Applications	Bioceram Dev Appl	0.958
Business & Financial Affairs	J Bus & Fin Aff	2.000
Generalized Lie Theory and Applications	J Generalized Lie Theory Appl	1.750
Irrigation & Drainage Systems Engineering	Irrigat Drainage Sys Eng	4.286
Industrial Engineering & Management	Ind Eng Manage	0.474
Aeronautics & Aerospace Engineering	J Aeronaut Aerospace Eng	1.407
Applied & Computational Mathematics	J Appl Computat Math	0.581
Architectural Engineering Technology	J Archit Eng Tech	1.071
Accounting & Marketing	J Account Mark	0.500
Aquaculture Research & Development	J Aquac Res Development	1.272
Bioengineering & Biomedical Science	J Bioeng Biomed Sci	1.235
Biometrics & Biostatistics	J Biomet Biostat	1.272
Biosensors & Bioelectronics	J Biosens Bioelectron	2.137
Civil & Environmental Engineering	J Civil Environ Eng	1.294
Cytology & Histology	J Cytol Histol	0.569
Civil & Legal Sciences	J Civil Legal Sci	0.286
Ecosystem & Ecography	J Ecosyst Ecogr	1.806
Electrical & Electronic Systems	J Elec Electron Syst	0.533
Earth Science & Climatic Change	J Earth Sci Clim Change	2.082
Geography & Natural Disasters	J Geogr Nat Disast	0.800
Hotel & Business Management	J Hotel Bus Manage	1.600
Information Technology & Software Engineering	J Inform Tech Soft Engg	2.789
Molecular Imaging & Dynamics	J Mol Imaging Dynam	2.091

Earth Science & Climatic Change	J Earth Sci Clim Change	2.082
Geography & Natural Disasters	J Geogr Nat Disast	0.800
Hotel & Business Management	J Hotel Bus Manage	1.600
Information Technology & Software Engineering	J Inform Tech Soft Engg	2.789
Molecular Imaging & Dynamics	J Mol Imaging Dynam	2.091
Petroleum & Environmental Engineering	J Pet Environ Biotechnol	2.839
Stock & Forex Trading	J Stock Forex Trad	0.300
Textile Science & Engineering	J Textile Sci Eng	0.667
Tourism & Hospitality	J Tourism Hospit	1.190
Telecommunications System & Management	J Telecommun Syst Manage	0.800
Physical Mathematics	J Phys Math	4.500
Nanomedicine & Nanotechnology	J Nanomed Nanotechnol	4.68
Arabian Journal of Business and Management Review	Arab J Bus Manage Rev	1.42
Research and Reviews: Journal of Engineering and Technology	Engineering and Technology	0.14
Journal of Material Sciences & Engineering	J Material Sci Eng	1.31
Journal of Mass Communication & Journalism	J Mass Communicat Journalism	0.62
Journal of Powder Metallurgy & Mining	J Powder Metall Min	0.71
Journal of Applied Mechanical Engineering	J Appl Mech Eng	1.65
Archives of Clinical Microbiology		0.35
Dentistry	Dentistry	1.22
Journal of Diabetes & Metabolism	J Diabetes Metab	1.77
Otolaryngology: Current Research	Otolaryngol (Sunnyvale)	0.22
Journal of Metabolic Syndrome	J Metabolic Synd	1.27
Journal of Primatology	J Primatol	0.53
Journal of Thyroid Disorders & Therapy	Thyroid Disorders Ther	0.43
Jounal of Novel Physiotherapies	J Nov Physiother	1.24
Journal of Stem Cell Research & Therapy	J Stem Cell Res Ther	2.78
Anatomy & Physiology: Current Research	Anat Physiol	1
Pancreatic Disorders & Therapy	Pancreat Disord Ther	0.54
Journal of Cancer Science & Therapy	J Cancer Sci Ther	4.203
Journal of Biomedical Sciences		0.2
Journal of Nutritional Disorders & Therapy	J Nutr Disord Ther	1.46
Medical & Surgical Urology	Med Surg Urol	0.3
Journal of Biochips & Tissue Chips	J Biochip Tissue Chip	1.7
Journal of Liver	J Liver	0.08
Journal of Family Medicine and Medical Research	Fam Med Med Sci Res	0.78
Gynecology & Obstetrics	Gynecol Obstet (Sunnyvale)	0.52
Journal of Integrative Oncology	J Integr Oncol	1.67
Journal of Neonatal Biology	J Neonatal Biol	0.55
Journal of Glycobiology	J Glycobiology	0.8
Journal of Blood & Lymph	J Blood Lymph	0.12
Journal of Arthritis	J Arthritis	1.87
Journal of Membrane Science & Technology	J Membra Sci Technol	1.18
Medicinal Chemistry	Med Chem (Los Angeles)	2.64
Journal of Physical Chemistry & Biophysics	J Phys Chem Biophys	0.75
Organic Chemistry: Current Research	Organic Chem Curr Res	1.94
Journal of Bioprocessing & Biotechniques	J Bioprocess Biotech	1.74
Journal of Environmental & Analytical Toxicology	J Environ Anal Toxicol	2.58
Journal of Chemical Engineering & Process Technology	J Chem Eng Process Technol	1.21
Journal of Computer Science & Systems Biology	J Comput Sci Syst Biol	1.62
Journal of Analytical & Bioanalytical Techniques	J Anal Bioanal Tech	2.16
Journal of Plant Biochemistry & Physiology	J Plant Biochem Physiol	2.28
Journal of Chromatography & Separation Techniques	J Chromatogr Sep Tech	1.78
Journal of Thermodynamics & Catalysis		0.91
Community Medicine & Health Education	J Community Med Health Educ	1.27
Epidemiology: Open Access	Epidemiology (Sunnyvale)	1.35
Obesity & Weight Loss Therapy	J Obes Weight Loss Ther	0.94
Pain & Relief	J Pain Relief	1.14
Palliative Care & Medicine	J Palliat Care Med	0.88
Steroids & Hormonal Science	J Steroids Horm Sci	0.65
Gastrointestinal & Digestive System	J Gastrointest Dig Syst	0.43
Hair: Therapy & Transplantation		0.6
Andrology	Andrology (Los Angel)	1.16
Endocrinology & Metabolic Syndrome	Endocrinol Metab Syndr	1.12
Internal Medicine		2.48
Sleep Disorders & Therapy	J Sleep Disord Ther	0.5
Nuclear Medicine & Radiation Therapy	J Nucl Med Radiat Ther	0.88
Alternative & Integrative Medicine	Altern Integr Med	1.11
Pulmonary & Respiratory Medicine	J Pulm Respir Med	1.01
Occupational Medicine Health Affairs	Occup Med Health Aff	0.85
Reproductive System & Sexual Disorders	Reprod Syst Sex Disord	1.25
Medical Diagnostic Methods		0.29
Blood Disorders & Transfusion	J Blood Disord Transfus	0.5
General Medicine	Gen Med (Los Angel)	0.86
Bioenergetics: Open Access	Bioenergetics	3.1
Chemotherapy: Open Access	Chemotherapy (Los Angel)	1.8
Clinical & Experimental Pathology	J Clin Exp Pathol	1.54
Carcinogenesis & Mutagenesis	J Carcinog Mutagen	1.9
Clinical Research & Bioethics	J Clinic Res Bioeth	0.95
Vaccines & Vaccination	J Vaccines Vaccin	1.8
Immunome Research	Immunome Res	7.1
Clinical & Experimental Ophthalmology	J Clin Exp Ophthalmol	1.11
Clinical & Experimental Dermotology Research	J Clin Exp Dermatol Res	0.5
Clinical & Experimental Cardiology	J Clin Exp Cardiolog	1.33
Clinical Microbiology: Open Access	Clin Microbiol	0.7
Anesthesia & Clinical research	J Anesth Clin Res	0.7
Mycobacterial Diseases	Mycobact Dis	0.9
Clinical Toxicology	J Clin Toxicol	1.39
Clinical Trials & Research	J Clin Trials	1.33
Antivirals & Antiretrovirals	J Antivir Antiretrovir	1.27
Fermentation Technology	Ferment Technol	3.44
Clinical & Cellular immunology	J Clin Cell Immunol	2.019
Allergy & Therapy	J Allergy Ther	0.762
Bacteriology & Parasitology	J Bacteriol Parasitol	2.025
Rheumatology: Current Research	Rheumatology (Sunnyvale)	1.522
Virology & Mycology	Virol Mycol	0.69
Clinics in Mother and Child Health	Clinics Mother Child Health	0.432
Womens Health Care	J Womens Health Care	0.79
Marine Science: Research & Development	J Marine Sci Res Dev	0.45
Plant Pathology & Microbiology	J Plant Pathol Microbiol	1.75
Geology & Geophysics	J Geol Geophys	0.91
FisheriesSciences	J Fisheries Sci	0.51
Fisheries and Aquaculture Journal	Fish Aquac J	0.69
Bioremediation & Biodegradation	J Bioremediat Biodegrad	2.1
Advances in Crop Science and Technology	Adv Crop Sci Tech	0.39
Journal of Remote Sensing & GIS	J Geophys Remote Sens	0.77
Biofertilizers & Biopesticides	J Biofertil Biopestic.	1.19
Hydrology: Current Research	Hydrol Current Res	1.12
Probiotics & Health	J Prob Health	0.69
Veterinary Science & Technology	J Veterinar Sci Technolo	2.5
Medicinal & Aromatic Plants	Med Aromat Plants	2.02
Forest Research	Forest Res	1.69
International Journal of Sensor Networks and Data Communications	Sensor Netw Data Commun	1.66
Innovative Energy Policies	Innov Energ Policies	0.88
Biodiversity & Endangered Species	J Biodivers Endanger Species	0.25
Biosafety	Biosafety	0.49
Agrotechnology	Agrotechnol	0.69
Journal of Traditional Medicine and Clinical Naturopathy	J Tradition Med Clin Naturopth	0.49
Nutrition & Food Sciences	J Nutr Food Sci	1.14
Entomology, Ornithology & Herpetology	Entomol Ornithol Herpetol	1.26

Impact Factor Calculation:

Impact Factor was established by dividing the number of articles published in 2012 and 2013 with the number of times they are cited in 2014 based on Google search and the Scholar Citation Index database. If 'X' is the total number of articles published in 2012 and 2013, and 'Y' is the number of times these articles were cited in indexed journals during 2014 than, impact factor = Y/X

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com









3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Supporting Journals

CNS 2017

Supporting Journals

Journal of Neurological Disorders

Journal of Neurology & Neurophysiology

Journal of Neurology and Neuroscience



Meet Inspiring Speakers and Experts at our 3000+ Global Events Every year on Medical, Pharma, Engineering, Science, Technology, Business and 40 Varient fields

AGRI, FOOD & AQUA

9th Global Food Safety Conference
Dec 04-06, 2017 Atlanta, USA

20th Global Food Processing & Technology Summit Dec 11-13 , 2017 Philadelphia, USA

2nd International Conference on
Food Microbiology
Nov 09-11, 2017 Madrid, Spain

5th International Food Safety, Quality & Policy Conference
Nov 27-28, 2017 Dubai, UAE

ALTERNATIVE HEALTHCARE

23rd International Conference on
Herbal and Alternative Remedies for Diabetes and Endocrine Disorders
Nov 02-04, 2017 Thailand, Bangkok

BIOCHEMISTRY

3rd International Conference on
Genetic and Protein Engineering
Nov 08-09, 2017 Las Vegas, USA

3rd International Conference on
Lipid Science & Technology
Dec 11-12, 2017 Madrid, Spain

CARDIOLOGY

21st International Conference on
Clinical & Experimental Cardiology
Nov 06-07, 2017 Las Vegas, USA

22nd World Cardiology Conference
Dec 11-12, 2017 Madrid, Spain

16th World Cardiology Congress
December 08-10, 2017 Dubai, UAE

3rd Global Summit on **Heart Diseases**
Nov 02-04, 2017 Thailand, Bangkok

CHEMICAL ENGINEERING

7th World Congress on
Petrochemistry and Chemical Engineering
Nov13-15, 2017 Atlanta, USA

2nd World Biodiesel Congress & Expo
Dec 04-05, 2017 Atlanta, USA

6th International Congress and Expo on
Biofuels, Bioenergy & Bioeconomy
Dec 04-06, 2017 Sao Paulo, Brazil

CHEMISTRY

7th International Conference on
Medicinal Chemistry & Computer Aided Drug Designing
Nov 02-04, 2017 San Antonio, USA

2nd International Conference on
Nuclear Chemistry
Nov 06-07, 2017 Las Vegas, USA

2nd International Conference and Exhibition on
Polymer Chemistry
Nov 06-08, 2017 Las Vegas, USA

7th Global Mass Spectrometry Congress
Dec 14-16, 2017 Dubai, UAE

DENTISTRY

37th Global Summit on
Dental Surgeons & Dental Materials
Nov 02-04, 2017 San Antonio, USA

38th Annual Congress on
World Dentistry
Nov 06-08, 2017 San Antonio, USA

26th American Dental Congress
Dec 04-06, 2017 Atlanta, USA

39th World Dental Congress Summit
Dec 04-06, 2017 Sao Paulo, Brazil

37th Asia Pacific Dental and Oral Care Congress
Nov 20-22, 2017 Australia, Melbourne

DIABETES AND ENDOCRINOLOGY

International Conference on
Diabetes, Metabolism & Obesity
Nov15-17, 2017 Las Vegas, USA

International Conference on
Diabetes and Endocrinology
Dec 06-08, 2017 Atlanta, USA

2nd International Conference on
Herbal and Alternative Remedies for Diabetes and Endocrine Disorders
Nov 02-04, 2017 Thailand, Bangkok

25th Global Diabetes and Medicare Expo
Dec 11-12, 2017 Dubai, UAE

ENVIRONMENTAL SCIENCES

4th International Conference on **GreenEnergy & Expo** Nov 06-08, 2017 Las Vegas, USA

5th International Conference on
Recycling: Reduce, Reuse and Recycle
Nov 06-08, 2017 Las Vegas, USA

EEE & ENGINEERING

6th International Conference on
Biostatistics & Bioinformatics
Nov13-14, 2017 Atlanta, USA

GASTROENTEROLOGY

2nd International Conference on
Hepatology & Gastroenterology
Nov 13-14, 2017 Las Vegas, USA

GENETICS & MOLECULAR BIOLOGY

2nd World Biotechnology Congress
Dec 04-05, 2017 Sao Paulo, Brazil

GEOLOGY & EARTH SCIENCE

2nd International Convention on
Geophysics and Geo technics
Nov 08-09, 2017 Las Vegas, USA

2nd International Convention on
Geosciences and Remote Sensing
Nov 08-09, 2017 Las Vegas, USA

Annual Congress on **Soil Sciences**
Dec 04-05, 2017 Madrid, Spain

HEALTHCARE MANAGEMENT

2nd International Conference on
Health & Hospital Management
Nov 06-07, 2017 Vienna, Austria

International Conference on
Medical Education
Nov 06-08, 2017 Vienna, Austria

IMMUNOLOGY

3rd Antibodies and Bio Therapeutics Congress
Nov 08-09, 2017 Las Vegas, USA

5th International conference on
HIV/AIDS, STDS & STIS
Nov 13-14, 2017 Las Vegas, USA

9th World Congress and Expo on
Immunology
Nov 02-03, 2017 Atlanta, USA

3rd International Conference on
Immunity, Inflammation and Immunotherapies
Nov 02-03, 2017 Atlanta, USA

2nd International Conference on
Autoimmunity
Nov 09-10, 2017 Madrid, Spain

World Immunology Congress
Dec 14-15, 2017 Dubai, UAE

INFECTIOUS DISEASES

3rd International conference on
Flu & Emerging Infectious Diseases
Nov 06-07, 2017 Las Vegas, USA

MATERIALS SCIENCE

13th International Conference and Exhibition on
Materials Science and Engineering
Nov13-15, 2017 Las Vegas, USA

14th International Conference on
Functional Energy Materials
Dec 06-07, 2017 Atlanta, USA

MICROBIOLOGY

2nd International conference on
Human Papillomavirus
Nov13-14, 2017 Las Vegas, USA

World Yeast Congress
Dec 06-07, 2017 Sao Paulo, Brazil

4th World Congress and Expo on
Applied Microbiology
Nov 09-11, 2017 Madrid, Spain

10th International Congress on
Clinical Virology
Dec 04-05, 2017 Dubai, UAE

Annual Congress on **Microbes and Infection**
Dec 04-05, 2017 Dubai, UAE

NANOTECHNOLOGY

22th International Conference and Expo on
Nanoscience and Molecular Nanotechnology
Nov 13-14, 2017 Vienna, Austria

19th International Conference on **Nanotek and Expo** Nov13-15, 2017 Atlanta, USA

17th Nanotechnology products and Summit
Nov13-15, 2017 Atlanta, USA

3rd Biomedical Engineering and Expo
Nov 07-08, 2017 Barcelona, Spain

NEUROSCIENCE

8th International Conference and Exhibition on
Addiction Research & Therapy
Nov 13-15, 2017 Las Vegas, USA

6th International Conference on
Brain Disorders and Therapeutics
Nov 06-08, 2017 Madrid, Spain

18th Global Neurologists Annual Meeting on
Neurology and Neuro Surgery
Nov 16-17, 2017 Vienna, Austria

13th Global Neurologists Annual Meeting on
Neurology and Neuro Surgery
Nov 27-28, 2017 Dubai, UAE

NURSING

46th Global Nursing and Healthcare Conference
Dec 06-07, 2017 Sao Paulo, Brazil

World Congress on
Nursing Pharmacology and Nursing Education
Nov 20-21, 2017 Melbourne, Australia

Meet Inspiring Speakers and Experts at our 3000+ Global Events Every year on Medical, Pharma, Engineering, Science, Technology, Business and 40 Varient fields

NUTRITION & OBESITY

16th International conference and Exhibition on
Obesity & Weight Management
Nov16-17, 2017 Atlanta, USA

17th World Fitness Expo
Nov 16-17, 2017 Atlanta, USA

ONCOLOGY & CANCER

World Medical and Clinical Oncology Congress Nov13-15 , 2017 Las Vegas, USA

9th International Conference on
Hematology and Hematological Oncology
Nov 08-09, 2017, Las Vegas, USA

International Conference on
Epigenetics
Nov 06-07, 2017 Madrid, Spain

World Cancer Convention
Nov 27-28, 2017 Dubai, UAE

International Conference on
Cancer Diagnostics
Nov 27-28, 2017 Dubai, UAE

OPHTHALMOLOGY

20th World Ophthalmology Summit
Dec 04-05, 2017 Sao Paulo, Brazil

18th European Ophthalmology Congress
Dec 07-09, 2017 Madrid, Spain

17th Global Ophthalmology and Glaucoma Conference
Nov 27-28, 2017 Dubai ,UAE

PATHOLOGY

2nd International conference on
Digital Pathology
Nov 02-03, 2017 San Antonio, USA

PEDIATRICS

5th Annual Conference on **Translational Medicine** Nov15-16, 2017 Las Vegas, USA

20th International Conference on
Neonatology and Perinatology
Dec 04-06, 2017 Madrid, Spain

PHARMACEUTICAL SCIENCES

European Biopharma Congress
Nov 16-17, 2017 Vienna, Austria

17th International Conference on
Nanomedicine and Nanotechnology in Health Care
Nov 23-24, 2017 Melbourne, Australia

10th International Conferences on
Immunopharmacology and Immunotoxicology
Nov 20-21, 2017 Melbourne, Australia

PHYSICAL THERAPY & REHABILITATION

6th International Conference on
Physiotherapy
Nov 27-28, 2017 Dubai, UAE

PHYSICS

8th International Conference and Exhibition on
Lasers, Optics & Photonics
Nov 02-04, 2017 San Antonio, USA

2nd International Conference on
Atomic and Nuclear Physics
Nov 8-9, 2017 Las Vegas, USA

International Conference on
High Energy Physics
Dec 11-12, 2017 Madrid, Spain

PSYCHIATRY

International Conference on
Psychiatry and Mental Health
Nov 20-21, 2017 Melbourne, Australia

10th World Psychiatrists Meet
Dec 07-08, 2017 Dubai, UAE

VACCINES

29th Global Vaccines & Vaccination Summit And Expo
Nov 30-Dec 1, 2017 Dubai, UAE

VETERINARY

9th Global Veterinary Summit
Nov15-16, 2017 Las Vegas, USA







3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Keynote Forum

Day 1

Dionisio Figueiredo Lopes, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-022




Dionisio Figueiredo Lopes

Hospital de Urgências Governador Otavio Lage, Brazil

The use of multislice CT angiography in the surgical treatment of ruptured intracranial aneurysms

Non-traumatic subarachnoid hemorrhage (SAH) is a neurological emergency. The main cause of non-traumatic SAH (80% of cases) is rupture of an intracranial aneurysm, an event accompanied by high morbidity and mortality rates. The incidence of aneurysmal SAH is estimated to be about 11 cases per 100,000 population per year. Extensive evidence is available demonstrating that early surgery is associated with improved outcome. Cerebral angiography (CA), computed tomography angiography (CTA) or MR angiography are commonly used to determine the location, size and shape of an aneurysm before treatment. CTA images show cerebral vessels in three-dimensional directions and can provide 3D images for aneurysm detection. Some studies have reported sensitivities ranging from 77 and 100% and specificities ranging from 79 and 100%. Among aneurysm detected on CTA and then undergoing surgery, 100% correlation was observed between CTA and CA. CTA, as less invasive and rapidly performed is an accepted method for detection and characterization of cerebral aneurysm when planning surgical intervention. Hospital de Urgências Governador Otávio Lage – HUGOL is a reference hospital for neurological emergencies such as trauma and stroke in a big city in Brazil. We proceeded 60 microsurgical clipping of ruptured intracranial aneurysm during 17 months from August 2015 to December 2016. After the clinical and image diagnoses of SAH, all the 60 patients underwent CTA examinations. The CTA study was performed with a 16-row multislice CT machine. One aneurysm (1.6%) was not detected by CTA initially and visible on the CA. 59 (98.3%) patients were successfully treated based on CTA as the only preoperative investigation. In conclusion, 16-slice CTA image is useful for the diagnosis of ruptured cerebral aneurysm as a noninvasive imaging technique providing an early diagnosis.



Biography

Dionisio Figueiredo Lopes is a Neurosurgeon Member of Brazilian Neurosurgery Society, member of Brazilian Neurosurgery Academy. He is the Head of Neurosurgery at Hospital de Urgências Governador Otavio Lage (HUGOL), a hospital reference in neurosurgical emergencies, Consultant at Hospital de Urgências de Goiânia and Hospital Santa Mônica. He is a Neurosurgeon with expertise in vascular diseases, brain tumor and traumatic brain injury. He has Fellowship in Neuro-oncology at Dresden/Germany and Fellowship in Advanced Techniques in Neurosurgery at Tubingen/Germany.

dioflopes@gmail.com

Antonio Scilimati, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-022



Antonio Scilimati

University of Bari, Italy

Neuroinflammation: Prodrome of neurological and neurodegenerative diseases

Brain inflammatory response, termed neuroinflammation, is crucial to protect the CNS. However, uncontrolled or prolonged neuroinflammation is harmful and could induce neuronal damage. This is particularly relevant in neurological and neurodegenerative diseases (i.e., Alzheimer and Parkinson diseases, amyotrophic lateral sclerosis, multiple sclerosis, traumatic brain injury, HIV dementia, and prion diseases), which are typified by evidence of microglial activation and neuroinflammation. Microglia, the resident immune cells in the brain, plays a role in immune surveillance. Once exposed to immunological challenges such as invading pathogens and neuronal injuries, microglia readily activate and undergo changes in morphology (hypertrophy), number (proliferation), and function (phagocytosis). As a consequence of their activation, microglia produce many pro-inflammatory factors and neurotoxic mediators including complement, arachidonic acid and its lipid metabolites (prostaglandins), cytokines, chemokines, nitric oxide and free radicals, several of which contribute directly to neuronal injury. Among the mechanisms involved into the neuroinflammatory complex network, the cyclooxygenase-1 (COX-1) (predominantly localized in microglia) plays a previously unrecognized role in the neuroinflammation as demonstrated by the attenuation of the inflammatory response and neuronal loss due to the genetic ablation or pharmacological inhibition of COX-1 activity. COX-2, the other known COX isoform, mainly localized in pyramidal neurons, is expected to predominantly contribute to increase prostaglandin biosynthesis in response to insults that directly challenge neurons, such as ischemia and excitotoxicity. In this context, the action of highly selective COX-1 inhibitors compared to coxibs (selective COX-2 inhibitors) in *in vitro* and *in vivo* neuroinflammatory state will be presented.

Biography

Antonio Scilimati graduated cum laude in Chemistry at the University of Bari (Italy) and PhD at the University of Wisconsin (USA). He worked for 4 years at MerckSerono plant producing recombinant drugs. Now, he is an Associate Professor at University of Bari, teaching Medicinal Chemistry. In "Medicinal Science", he uses the theranostic approach to target the cyclooxygenase (COX)-1 as a novel biomarker in oncology and neuroinflammation.

antonio.scilimati@uniba.it

Notes:

Hanan Sheikh Ibrahim, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-022



Hanan Sheikh Ibrahim

[1]Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, USA

[2]Cleveland Clinic Abu Dhabi, UAE

Pseudobulbar affect, cognitive dysfunction and depression in poorly controlled diabetes

A case of unrecognized neurocognitive disorder and pseudo-bulbar affect in a patient with multiple vascular risks, poorly controlled diabetes with subcortical lacunes masquerades as depression. 64 year old ex-smoker male with PMH of hypertension, long standing poorly controlled type 2 diabetes presented with insomnia and depressive mood, where a trial of SNRI was partially effective in his mood control but did not help with his crying bursts. He is still driving with multiple episodes of loss of consciousness due to hypoglycemia. His physical exam was unremarkable except for emotional bursts of laughter and crying that were not affect congruent. On CGA, he was found to have 3 impaired IADL domains (ability to drive with many car accidents, handling finances and administering medication. His cognition test showed MMSE : 26/30, adjusted to education level, he had impaired clock drawing test and impaired trail B test, impaired speed, attention and executive skills, GDS was 4/15, FRAIL scale was 4/5. His labs revealed HbA1c above 10, He has normal B12, folate. His MRI revealed white matter disease, pontine infarct, Left thalamic lacunar infarct and left lenticular lacune as well in addition to cortical atrophy. Patient was recognized as an early vascular Dementia case with associated Pseudo bulbar Affect masked by depressive symptoms, the case triggered a change of his holistic care that revamped his HbA1C goals and advanced care planning. In summary, General psychiatrists and Primary care clinicians may fail to recognize pseudo bulbar affect and cognitive dysfunction during clinic visits using routine history and physical Pseudobulbar Affect (PBA), presents as abrupt episodes of uncontrollable laughter or crying that are incongruent or independent of mood, occurs in many neurological brain diseases or following brain injury. It is important to identify PBA as a different entity from depression, treat and identify underlying vascular cognitive impairment.

Biography

Hanan Sheikh Ibrahim is a Clinical Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Ohio, a Consultant Physician and a Quality Officer at the Cleveland Clinic Abu Dhabi. She was trained at Cleveland Clinic in Ohio, USA under the tutelage of Dr. Robert Palmer, Concept Originator of the Acute Care of Elderly (ACE) unit which was modeled internationally. Then she pioneered in the geriatric care in the UAE by establishing the first MACE unit and the first Geriatric Core Curriculum for resident physicians in training. She received her MD from Damascus University, Syria where she specialized in Pulmonary Medicine then she moved to US where she completed her residency in Internal Medicine at the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania, US. She completed her Fellowship in Geriatric Medicine at Cleveland Clinic, Ohio. She is board certified in Internal & Geriatrics Medicine.

ibrahihccf@yahoo.com
hanan101@hotmail.com

Notes:







3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Scientific Tracks & Abstracts

Day 1

Session Chair
Dionisio Figueiredo Lopes
Hospital de Urgencia Otavio Lage, Brazil

Session Co-Chair
Khin Bo Maung
Northern Lincolnshire and Goole NHS Foundation Trust, United Kingdom

Session Introduction

Title: Challenges in awake craniotomy for intrinsic brain tumors in eloquent cortex

Debabrata Mukhopadhyay, Kailash Group of Hospitals, India

Title: Pyrethroid bifenthrin induces neuronal damage, cognitive impairment associated with oxidative damage in rat's hippocampus : Possible involvement of Nurr1/Nrf2 and nf-kb pathways

Brahim Gargouri, University of Freiburg Medical School, Germany

Debabrata Mukhopadhyay et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Challenges in awake craniotomy for intrinsic brain tumors in eloquent cortex

Debabrata Mukhopadhyay and **Anil Gurnani**
Kailash Group of Hospitals, India

Introduction: Surgical treatment of brain tumors in the eloquent areas has high risk of eloquent impairment. These tumors represent a unique challenge as most of the patients have a higher risk of treatment related complications. Awake craniotomy is a useful surgical approach to help to identify and preserve functional areas in the brain and maximizes tumor removal and minimizes complications.

Methods: Selected patients admitted with intrinsic brain tumor between from July, 2011 to August, 2016 in the eloquent area of brain like speech or motor area were chosen for awake craniotomy. A retrospective analysis was done. A preoperative assessment was also done. These patients were presented with seizure and/or progressive neurological deficit like speech or motor. A standard anaesthesia monitoring was done during surgery. Long acting local anaesthesia (Bupivacaine) was used for scalp block. The surgeries were performed in a state of sleep-awake-sleep pattern, keeping the patients fully awake during tumor removal. Propofol and Fentanyl was used as anaesthetic agents which was completely withdrawn prior to tumor removal. The speech and motor functions were closely monitored clinically by verbal commands during tumor resection. No brain mapping was performed due to lack of resources. All patients underwent non-contrast computed tomogram head in the first post-operative day.

Results: A total of 35 patients were included in the study. The oldest patient was 55 years and youngest being 24 years (mean 36 years). Twenty (57.14%) were females and 15 (42.85%) males. Twenty (57.14%) patients were presented with predominantly seizure disorders and rest with progressive neurological deficit like speech or motor. Thirty (85.71%) patients were discharged on second postoperative day. Complications was encountered in 4 (11.42%) patients who developed brain swelling intraoperatively and 5 (14.28%) deteriorated neurologically in the immediate postoperative period however managed successfully and discharged in a week's time. Five (14.28%) patients require ICU/HDU care for different reasons. There was no mortality during the hospital stay. Histopathology revealed 25 (71.42%) patients had low grade glioma, 8 (22.85%) had high grade glioma and 2 (5.71%) had metastases.

Conclusion: Awake craniotomy is a safe surgical management for intrinsic brain tumors in the eloquent cortex although surgery and anesthesia is a challenge. It offers great advantage towards disease outcome. However long follow up and more studies are required.

Biography

Debabrata Mukhopadhyay is currently working as a Neurosurgeon in the Department of Neurosurgery at Kailash Group of Hospitals, India. He has published several articles in the reputed and peer reviewed journals and participated in several scientific events.

neurodoc07@gmail.com

Brahim Gargouri et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Pyrethroid bifenthrin induces neuronal damage, cognitive impairment associated with oxidative damage in rat's hippocampus: Possible involvement of Nurr1/Nrf2 and NFkb pathways

Brahim Gargouri[1], Yassine Chtourou[1], Michèle Bouchard[2], Abdelmajid Khabir[3], Bernd L Fiebich[3] and **Hamadi Fetoui[1]**
[1]University of Sfax, Tunisia
[2]Université de Montréal, Canada
[3]Habib Bourguiba Hospital, Tunisia
[4]University of Freiburg Medical School, Germany

Substantial evidence has shown that exposure to pyrethroid pesticides may cause adverse neurodevelopmental outcomes and cognitive impairment, but the underlying neurobiological mechanism is poorly understood so far. In this study, we investigated the alterations of neuronal damage, glial activation oxidative stress and cholinergic dysfunction, and their causal relationship with the cognitive deficits induced by bifenthrin. Our results revealed that exposure to bifenthrin for 8 weeks at doses 6 and 21 mg/kgbw leads to reduction in the levels of acetyl-cholinesterase, Na^+/K^+, $Ca2^+$, $Mg2^+$ ATPases, enzymatic and non-enzymatic antioxidants activities in the hippocampus region. Further, in hippocampus tissue, bifenthrin significantly enhance the mRNA gene expression of nuclear receptor related 1 protein (nurr1), nuclear factor erythroid 2 (nrf2) and nuclear factorkB pathway (NFkB). Oxidative/nitrosative stress was evident in bifenthrin-treated groups by increased malondialdehyde (MDA), protein carbonyls (PCO), and nitrite concentration (NO) in hippocampus. Further, we found that treated rats with bifenthrin exhibited spatial learning and memory impairments and working memory dysfunction compared with control rats. This is also supported by histopathological findings of hippocampus region of rats. Correlational analyses revealed that spatial learning and memory impairments and working memory dysfunction were significantly correlated with the measures of neuronal damage, cholinergic dysfunction and oxidative damage in the hippocampus of treated rats. Moreover, the measures of neuronal damage and central cholinergic dysfunction were significantly correlated with the indexes of oxidative damage in treated rats. The results of the present study suggest that neuronal damage, cholinergic dysfunction and oxidative damage in the hippocampus following bifenthrin exposure could be involved in cognitive deficits.

Biography

Brahim Gargouri is currently working in the Laboratory of Toxicology-Microbiology and Environmental Health at University of Sfax, Tunisia. He has published several original research papers in the reputed and peer reviewed journals.

brahimovic1987@gmail.com

Notes:

Session Chair
Antonio Scilimati
University of Bari, Italy

Session Co-Chair
Hanan Sheikh Ibrahim
Cleveland Clinic Abu Dhabi, UAE

Session Introduction

Title: **Reactive cuprizone-induced changes in neurons of central nervous system, behavioral reactions and its recovering after influence of leukemia inhibitory factor in mice of different ages**

Melnyk Nataliia O, O O Bogomolets National Medical University, Ukraine

Title: **Neuroprotective effect of exogenous melatonin on the noradrenergic neurons of adult male rats' locus coeruleus nucleus following REM sleep deprivation**

Seyed Behnamedin Jameie, Iran University of Medical Sciences, Iran

Melnyk Nataliia O et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Reactive cuprizone-induced changes in neurons of central nervous system, behavioral reactions and its recovering after influence of leukemia inhibitory factor in mice of different ages

Melnyk Nataliia O[1,2], Labunets I F[1], Rodnichenko A E[1], Rymar S E[1] and **Utko N A[1]**
[1]State Institute of Genetic and Regenerative Medicine - NAMS, Ukraine
[2]O O Bogomolets National Medical University, Ukraine

Statement of the Problem: Investigation work was aimed at studying the features of neuroprotective effects of recombinant human leukemia inhibitory factor (rhLIF) on mice of different ages with cuprizone model of demyelination.

Methodology & Theoretical Orientation: In 129/Sv mice at 3-5 and 16-17 months of age, after staining histological sections of brain and spinal cord toluidin blue, were determined the percentage of neurons with unmodified, moderate and severe structural changes. Motor and emotional activity in "open field" test, activity of brain antioxidant enzymes and macrophages capable to phagocytosis of latex beads were assessed. Cuprizone was fed daily for 3 weeks. RhLIF injected after 7 days cuprizone diet, daily, 50 μg/kg. In cuprizone-treated mice of both age groups, increase in the brain and spinal cord proportions neurons with severe changes was observed.

Findings: In young animals, which received cuprizone and rhLIF reduces the amount of neurons with destructive changes. Such changes under influence of rhLIF are slowly observed in older mice. Cuprizone decreases the amount of crossed squares and faecal boluses in mice of both age groups. Inhibition amount and activity of macrophages after injections of the rhLIF presents only for older mice. LIF may be perspective neuroprotective drug in multiple sclerosis. The injections of rhLIF restore emotional activity in these mice, but the increase in motor activity is observed only in young mice. In brain of cuprizone-treated mice of different ages inhibited the activity of catalase and glutathione peroxidase (GP); changes were more pronounced in older mice. The positive effect of rhLIF on GP activity appears only in young mice. Percentage of active macrophages increases in cuprizone-treated mice of both age groups, but their activity is only in 16-17 month-old mice.

Biography

Melnyk Nataliia O was investigating demyelination and remyelination process in central nerve system in experiment animals (in rats and mice). She studied structural changes in organs central and peripheral immune system in demyelination condition. She has 262 scientific works (4 patents) and is working in National O O Bogomolets Medical University where she provides lecture courses in Histology, Cytology and Embryology. She has prepared and edited textbook, "*Histology, Cytology, Embryology*".

melnikn@mail.ru

Notes:

Seyed Behnamedin Jameie et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Neuroprotective effect of exogenous melatonin on the noradrenergic neurons of adult male rats' locus coeruleus nucleus following REM sleep deprivation

Seyed Behnamedin Jameie[1], Somaye Mesgar[2], Abbas Aliaghaei[2], Fariba Khodagholi[2], Samira Danyali[2], Mohammad Amin Abdollahifar[2], Marziyeh Sorraya[2] and **Yousef Sadeghi[2]**

[1]Iran University of Medical Sciences, Iran

[2]Shahid Beheshti University of Medical Sciences, Iran

Background: Melatonin primarily secrets by the pineal gland in dark phase of the circadian rhythm. In addition to its role as an internal sleep facilitator, melatonin acts as an antioxidant, anti-inflammatory and neuroprotective agents. Recently, melatonin has been introduced as a therapeutic strategy for sleep disorders. Hence, in the present study, we studied the neuroprotective effects of pre- and post-treatment of melatonin in locus coeruleus nucleus (LC) of rapid eye movement (REM) sleep deprived (REM-SD) male adult rats.

Methodology: Adult male rats of control, sham and trial groups were used in this study. By using flower-pot technique, short term REMSD was induced. Exogenous melatonin (ExMe) was used intraperitoneally in two forms of pre and post treatment. The protein level of cleaved caspase-3, number and density of tyrosine hydroxylase (TH) positive neurons and microglia population in LC was studied by Western blot and immunohistochemistry respectively. Morphological changes of LC nucleus and its neurons were also studied by using stereological analysis.

Results: The number of neurons and volume of LC was reserved in animals received post-RSD ExMe, apoptosis significantly was decreased comparing to RSD and Pre-RSD animals. Melatonin post-treatment of RSD rats also decreased cleavage of caspase-3 and increased reduced glutathione content in LC. Moreover, immunohistochemistry analysis revealed the increase number of TH positive neurons and decrease microglia migration.

Conclusion: Based on our findings, antioxidant properties of exogenous melatonin could play a critical role in certain type of sleep disorders.

Biography

Seyed Behnamedin Jameie is currently working as a Professor in the Neuroscience Research Center (NRC) at Iran University of Medical Sciences, Tehran, Iran. He has published several original research papers in the reputed & peer reviewed journals and also participated into several scientific meetings.

behjame@gmail.com

Notes:

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com









3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Keynote Forum

Day 2

CNS 2017

Khin Bo Maung, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-022



Khin Bo Maung

Northern Lincolnshire and Goole Hospitals NHS Foundation Trust, UK

Multiple sclerosis, corpus callosum & bedside test

Demyelination affects highly myelinated structures like Corpus Callosum (CC). CC is unique in function that it connects right and left hemisphere. It synchronises bimanual or bipedal activities. Affecting CC can disturb synchrony between the two hemispheres and will affect bimanual and bipedal tasks. The aim is to see if speed of clapping (bimanual activity) can reflect the involvement of CC in multiple sclerosis. Consecutive 70 multiple sclerosis patients from outpatient clinics and home visits were tested for bimanual hand function (clapping). Exclusion criteria are upper limb power <3/5 MRC scale, pain, visual impairment, intentional tremors, stroke or cognitive impairment. Study period started from 01-09-2016. Comparison of speed between rapid supination/pronation of left and right hand separately and then clapping of both hands (supination/pronation of each hands alternatively). Patients had to do as fast as they could. Noticeable slowing of clapping compared to single hand supination/pronation was taken as a sign slowing down of conduction through CC. 31 patients were excluded, 34 patients showed no noticeable difference, 2 patients were difficult to make conclusions and 3 patients showed definite slowing down in clapping. Positive patients will have difficulties in doing bimanual activities like using two sticks for mobility, typing using keyboard, pushing wheel chair bimanually, etc. It is possible to detect CC involvement by doing above bedside test and can be used in rehabilitation setting. Sample size is not large enough and larger studies are needed to validate the finding.

Biography

Khin Bo Maung is involved in Neurorehabilitation over 20 years. He is also a Lecturer (Hon) in Hull and York Medical School teaching 4th Year Medical Students in CNS and Musculoskeletal Blocks. He is doing Botulinum Toxin injection in Spasticity, Dystonia and Involuntary Movement disorders over 15 years. He has given poster and oral presentations in international neurorehabilitation conferences. He is also involved in using Functional Electrical Stimulation (FES) over 10 years and presented regularly in International FES Conferences. He is working on developing Hypertonic Hand Monitoring Scale.

bokhinmaung@yahoo.co.uk

Notes:

Alessandro M Morelli, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-022



Alessandro M Morelli

University of Genoa, Italy

Metabolism of myelin in health and pathology

Myelin is a site of active aerobic energy metabolism, producing ATP through the oxidative phosphorylation (OXPHOS) machinery, which contributes to the acceleration of nervous impulse. This innovative view simplifies current ideas about the physical chemical mechanisms that ensures the advancement of the action potential (CAP) as such basic mechanisms are unchanged in the passage of the CAP from the non-myelinated to myelinated axon. The ATP produced in myelin sheath is transferred to the axon through the Gap Junctions, which are abundant in myelin sheath. The OXPHOS proteins expresses in myelin is closely related to that of mitochondria and hence there must be some process still to be defined, which guarantees the transfer of OXPHOS machinery from mitochondria to myelin; overall the mitochondria-myelin link is known since many mitochondrial pathologies primarily affect myelin. For perfect functioning, OXPHOS requires an active synthesis of the heme group, considering that it is a fundamental component of several subunits of respiratory complexes, and interestingly, myelin sheath displays a higher heme group synthesis in comparison with other districts. In particular, proper functioning of myelin is closely linked to an efficient biosynthetic pathway of the heme and the crucial passage is catalyzed by the enzyme ALA dehydratase (EC 4.2.1.24) that requires zinc as cofactor. Lead poisoning (Saturnism) results in an imbalance of this enzyme and myelin degeneration. Moreover, analyzing the OXPHOS metabolism in myelin isolated from autopsy specimens of multiple sclerosis (MS) patients, we have observed a defective energy/respiratory capacity. With this knowledge, the hypothesis that MS is not an autoimmune disease, but a disease triggered by myelin degeneration following a malfunction of some process related to its energy function and heavy metal pollution seems confirmed, also considering the historical link between industrialization and the MS onset.

Biography

Alessandro M Morelli carried out research in varied fields of biology, focusing in those areas most directly linked to medicine. He investigated on the enzyme Glucose-6-P-dehydrogenase and on its molecular mechanism of senescence. He has been working in the phototransduction molecular events in photoreceptor cells of vertebrate retina. He has discovered the protein FX, a NADP dependent enzyme, catalyzing synthesis of GDP-L-fucose. He has been working on the effects of electromagnetic fields of extremely low frequency on the activity of enzymes involved in phototransduction in retinal cells of vertebrates. Moreover, he has put in evidence the reversible effects of electromagnetic fields on lipid-linked enzymes such as acetylcholinesterase of retinal synaptosomes. Recently, with Isabella Panfoli, Silvia Ravera, Daniela Calzia, he has discovered the brain myelin energetic function and the ATP extramitochondrial synthesis operating in it, involving new paradigms for neurobiology, with application in the study of multiple sclerosis and other neurodegenerative diseases.

morellia@unige.it

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com









3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Scientific Tracks & Abstracts

Day 2

Session Chair
Khin Bo Maung
Northern Lincolnshire and Goole NHS Foundation Trust
United Kingdom

Session Co-Chair
Hanan Sheikh Ibrahim
Cleveland Clinic Abu Dhabi, UAE

Session Introduction

Title: **Neuromyelitis optica: A case report**

Abdel Wahhab O Gh, V N Karazin Kharkiv National University, Ukraine

Title: **Effects of 660nm low-level laser therapy on P2X3 expression of lumbar DRG of adult male rats with neuropathic pain**

Seyed Behnamedin Jameie, Iran University of Medical Sciences, Iran

Delich O B et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Neuromyelitis optica: A case report

Delich O B[1], **Abdel Wahhab O Gh**[1], **Merkulova O Yu**[1], **Pasyura I N**[2] and **Shevchenko L M**[2]
[1]V N Karazin Kharkiv National University, Ukraine
[2]Kharkiv Railway Clinical Hospital 1of Branch "Health Center" of the Public joint stock company "Ukrainian Railway"

A 54-year-old woman was treated initially with neuritis of right optic nerve in 2013 that resolved completely. Two years later, she presented with relapse and partial visual functions recovery of right optic nerve. Ophthalmoscopy analysis showed atrophic changes of the disc optic nerve. After undercooling in March 2016, a patient complained of interscapular pain, weakness of the right limbs and urinary retention. MRI of thoracic part of spinal cord showed high T2 signal spread at least more than three vertebral segments, osteochondrosis. CT-angiography of spinal cord showed an absence of vascular malformations. A patient was treated with dexamethasone, ceftriaxone, vascular and metabolic therapy and was discharged with partial recovery, but interscapular pain was still present, sensory impairments from Th6 level down, urinary retention and constipation were revealed. From June 2016, she developed the lower spastic paraplegia. MRI of the brain (2015) didn't reveal any local change of the brain tissues, besides asymmetric hydrocephalus of the lateral ventricles. Biochemical analysis serum antibodies IgG, the specific markers of neuromyelitis optica (NMO), connected with aquaporin -4-(AQP4) usually led to increase of AQP4 concentration, which was 1:320 in our case. Course treatment included solumedrol, aciclovir, ceraxon, actovegin, and cytostatic drugs. The patient was discharged with certain improvements and diagnosed with NMO, partial atrophy of the disc right optic nerve, lower paraplegia, reduced sensitivity in trunk and right lower limb, pelvic sphincter disturbances. From September 2016, the patient started to use copaxone (40 mg/ml 3 times a week s.c. for 4 months). Pain in upper thoracic, cervical parts of vertebra with irradiation to the occipital region increased after respiratory infection in December 2016. The numbness spread to Th4-Th5 segments, appear the clinic of lower paraplegia. She got plasmapheresis as an out-patient one time. Every month from September 2016 to March 2017, infusion of methylprednisolone was performed (1000 mg), rituximab (375 mg/kg i.v. infusion every 10 days №4 from February to March). So, clinical diagnosis now is Neuromyelitis optica (Devic`s disease), remitting course, exacerbation, lower spastic paraplegia, pelvic sphincter disturbances by type of urinary retention and constipation, of the right disc optic nerve atrophy.

Biography

DELICH Olena: Currently a student and head of scientific society of the medical faculty of V.N. Karazin Kharkiv National University, Ukraine.
ABDEL WAHHAB O GH: Currently he is a student of the medical faculty of V.N. Karazin Kharkiv National University, Ukraine.

alena.deliya@gmail.com
igor.pasyura@yahoo.com
olga.merkulova64@gmail.com

Seyed Behnamedin Jameie et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-023

Effects of 660 nm low-level laser therapy on P2X3 expression of lumbar DRG of adult male rats with neuropathic pain

Seyed Behnamedin Jameie[1], Sajad Hassanzadeh[1], Mahdieh Kerdari[1], Ghazal Hamid Behnam[2], Mona Farhadi[1,3], Masumeh Masoumipoor[1], Manasadat Jameie[1,4] and **Melikasadat Jameie[1,4]**

[1]Iran University of Medical Sciences, Iran
[2]Islamic Azad University, Tehran, Iran
[3]Islamic Azad University, Karaj Branch, Iran
[4]Shahid Beheshti University of Medical Sciences, Iran

Background: Neuropathic Pain (NP) is a serious suffering medical condition that frequently leads to disability and life style changes. Although the exact mechanisms of NP are still unknown, recently the role of reactive oxygen species (ROS) reported as an important factor for NP. Apoptosis, increase of ATP production and reduction of antioxidants are also the other factors influencing NP. There are certain therapeutic procedures for NP, among them using laser therapy newly received more attention. In the present research, we studied the molecular effects of Low Level Laser Therapy (LLLT) on a rat model of NP.

Material & Methods: Thirty adult male Wistar rats (200-250 g) that are randomly divided into three groups including chronic constriction injury (CCI), CCI+LLLT and control were used in this study. CCI technique was used to induce NP. Laser therapy was done by using laser beam of 660 for 14 days following CCI. After that, expression of P2X3 of the DRG, Bax and Bcl2 in lumbar spinal segments measured by Western blotting. Level of glutathione (GSH) was also measured in lumbar spinal cord segments by Continuous Spectrophotometric Rate Determination method. For behavioral study, the mechanical and thermal hyperalgesia were evaluated in days 7 and 14 after CCI.

Results: LLLT for two weeks increased expression of Bcl2 and GSH, whereas decreased Bax and P2X3 expression significantly. Comparing the results of behavioral study showed significant differences in the mechanical and thermal threshold showed between CCI and CCI+ LLLT groups.

Conclusion: Based on our findings, the therapeutic effects of LLLT for NP act throughout cellular and molecular mechanisms which improve mitochondrial function that in turn improve cell function and prevent apoptosis.

Biography

Seyed Behnamedin Jameie is currently working as a Professor in the Neuroscience Research Center (NRC) at Iran University of Medical Sciences, Tehran, Iran. He has published several original research papers in the reputed & peer reviewed journals and also participated into several scientific meetings.

behjame@gmail.com

Notes:







3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Posters

Delich O B et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Neuromyelitis optica: A case report

Delich O B[1], **Abdel Wahhab O Gh**[1], **Merkulova O Yu**[1], **Pasyura I N**[2] and **Shevchenko L M**[2]
[1]V N Karazin Kharkiv National University, Ukraine
[2]Kharkiv Railway Clinical Hospital No1 of Branch "Health Center" of the Public joint stock company "Ukrainian Railway"

A 54-year-old woman was treated initially with neuritis of right optic nerve in 2013 that resolved completely. Two years later, she presented with relapse and partial visual functions recovery of right optic nerve. Ophthalmoscopy analysis showed atrophic changes of the disc optic nerve. After undercooling in March 2016, a patient complained of interscapular pain, weakness of the right limbs and urinary retention. MRI of thoracic part of spinal cord showed high T2 signal spread at least more than three vertebral segments, osteochondrosis. CT-angiography of spinal cord showed an absence of vascular malformations. A patient was treated with dexamethasone, ceftriaxone, vascular and metabolic therapy and was discharged with partial recovery, but interscapular pain was still present, sensory impairments from Th6 level down, urinary retention and constipation were revealed. From June 2016, she developed the lower spastic paraplegia. MRI of the brain (2015) didn't reveal any local change of the brain tissues, besides asymmetric hydrocephalus of the lateral ventricles. Biochemical analysis serum antibodies IgG, the specific markers of neuromyelitis optica (NMO), connected with aquaporin -4-(AQP4) usually led to increase of AQP4 concentration, which was 1:320 in our case. Course treatment included solumedrol, aciclovir, ceraxon, actovegin, and cytostatic drugs. The patient was discharged with certain improvements and diagnosed with NMO, partial atrophy of the disc right optic nerve, lower paraplegia, reduced sensitivity in trunk and right lower limb, pelvic sphincter disturbances. From September 2016, the patient started to use copaxone (40 mg/ml 3 times a week s.c. for 4 months). Pain in upper thoracic, cervical parts of vertebra with irradiation to the occipital region increased after respiratory infection in December 2016. The numbness spread to Th4-Th5 segments, appear the clinic of lower paraplegia. She got plasmapheresis as an out-patient one time. Every month from September 2016 to March 2017, infusion of methylprednisolone was performed (1000 mg), rituximab (375 mg/kg i.v. infusion every 10 days №4 from February to March). So, clinical diagnosis now is Neuromyelitis optica (Devic`s disease), remitting course, exacerbation, lower spastic paraplegia, pelvic sphincter disturbances by type of urinary retention and constipation, of the right disc optic nerve atrophy.

Biography

DELICH Olena: Currently a student and head of scientific society of the medical faculty of V.N. Karazin Kharkiv National University, Ukraine. ABDEL WAHHAB O GH: Currently he is a student of the medical faculty of V.N. Karazin Kharkiv National University, Ukraine. MERKULOVA Olga: Currently working as an associate professor in the department of neurology at V.N. Karazin Kharkiv National University, Ukraine. PASYURA Igor: Currently working as a the head of department of Neurology at Kharkiv Railway Clinical Hospital of №1 Branch "Health Center" of the Public joint stock company "Ukrainian Railway", Ukraine. SHEVCHENKO L M: Currently working as a doctor in the department of Neurology at Kharkiv Railway Clinical Hospital of №1 Branch "Health Center" of the Public joint stock company "Ukrainian Railway", Ukraine.

alena.deliya@gmail.com
igor.pasyura@yahoo.com
olga.merkulova64@gmail.com

Toshio Obata, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Protective effect of histidine on para-nonylphenol enhances 1-methyl-4-phenylpyridinium ion-induced hydroxyl free radical generation in rat striatum

Toshio Obata
Osaka Aoyama University, Japan

The present study examined the antioxidant effect of histidine, a singlet oxygen (1O2) scavenger, on para-nonylphenol, an environmental estrogen-like chemical, enhances 1-methyl-4-phenylpyridinium ion (MPP+)-induced hydroxyl radical (•OH) generation in extracellular fluid of rat striatum. Rats were anesthetized, and sodium salicylate in Ringer's solution (0.5 nmol/ l/min) was infused through a microdialysis probe to detect the generation of •OH as reflected by the non-enzymatic formation of 2,3-dihydroxybenzoic acid (DHBA) in the striatum. Induction of para-nonylphenol (10 M) significantly enhanced MPP+-induced •OH generation. However, histidine (25 mM) decreased the para-nonylphenol-induced •OH formation. Although the level of MPP+-induced •OH formation trapped as DHBA after para-nonylphenol treatment increased, para-nonylphenol failed to increase either the level of dopamine (DA) and DHBA formation in the reserpinized anuimals. When iron (II) was administered to para-nonylphenol (10 M)-pretreated rats, iron (II) clearly produced a dose-dependent increase in •OH formation, compared with MPP+-only treated animals, that showed a positive linear correlation between iron (II) and DHBA (R2=0.983) in the dialysate. However, in the presence of histidine (25 mM), small increase in the level of DHBA products were observed. These results indicate that para-nonylphenol enhanced •OH generation on $^1O_2$ production, and histidine may have preventive effect on para-nonylphenol and MPP+-induced •OH generation in rat striatum.

Biography

Toshio Obata is currently working as a Professor in the Department of Nursing at Faculty of Health Sciences, Osaka Aoyama University, Japan. He has published several original research papers in the reputed journals and also participated into several scientific meetings.

shibata@tnsic.com

Notes:

Dmitryi V Chistyakov et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

ARE-binding factors TTP and HUR reveal antagonistic relationships within glioma-related gene networks

Dmitryi V Chistyakov and **Alina A Astakhova**
A N Belozersky Research Institute of Physico-Chemical Biology - MSU, Russia

Statement of the Problem: Glioma is a heterogeneous group of primary brain tumors with poor prognoses. Effective treatment strategies for glioma have yet to be developed. This requires better understanding of molecular mechanisms involved into pathology, determining promising drug targets. Recently, it has become clear that mRNA stability regulation by Adenine-Uridine Rich Element (ARE) binding factors plays crucial role in cancer biology. This study aimed to unravel participation of ARE-binding factors TTP, HUR, BRF1, BRF2, KSRP, AUF1 in gene networks of gliomas.

Methodology & Theoretical Orientation: Data on gene expression in 276 glioma samples and 8 samples of healthy brain tissue were downloaded from Gene Omnibus (ID: GSE16011). Differential expression of the ARE-binding factors; correlations in expression patterns of the ARE-factors and other genes; biological functions of genes with associated expression patterns were analyzed.

Conclusion & Significance: Among ARE-binding factors TTP, BRF1, BRF2, KSRP but not HUR were upregulated at an mRNA level in brain tumors. Genes, correlating with ARE-factors by their expression patterns, split into two large subgroups: those that positively correlated with TTP and negatively correlated with HUR and vice versa. Interestingly, TTP-positive/HUR-negative genes were enriched in innate immune response mediators and TTP-negative/HUR-positive genes were enriched in RNA binding factors. Moreover, TTP associated genes were previously recognized as glioma survival prognosis markers. The obtained data demonstrate that ARE-binding factors are involved into glioma biology on a transcriptome level, reveal antagonistic relations between TTP and HUR and indicate that an ARE-mediated mRNA stability control pathway represents a promising target for tumor treatment strategies development. The research was supported by RFBR grant №16-34-01085 mol_a.




Fig. 1. Relationships between ARE-binding factors and genes, forming networks in glioma transcriptome. Red arrows determine positive and green arrows depict negative correlation on a transcription level between ARE-binding factors and genes forming group with distinguished biological functions.

Biography

Dmitryi V Chistyakov has his expertise in cell signaling pathways controlling inflammatory responses within the central nervous system. His scientific interests concern mechanisms that control innate immune response within nervous tissue on cellular level. Investigations within this field have brought him to the question about mRNA stability control during inflammatory response on the level of cells. These two processes – activation of innate immune response and post-transcriptional gene expression regulation turned out to be crucial for glioma development as well. Understanding their interaction during tumor development is one of the attractive directions of his research development.

chistyakof@gmail.com

Notes:

Dmitryi V Chistyakov et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Astroglial cell cultures do not produce resolvin D1 in course of LPS-induced response

Dmitryi V Chistyakov[1], **Alina A Astakhova**[1], **Marina G Sergeeva**[1] and **Nadezda V Azbukina**[2]
[1]A N Belozersky Research Institute of Physico-Chemical Biology - MSU, Russia
[2]Moscow State University, Russia

Statement of the Problem: Neuroinflammation is an innate immune response that accompanies numerous disorders within CNS, including neurodegenerative conditions like Alzheimer's disease, Parkinson's disease, stroke, cancer and others. In spite of its primary protective role, neuroinflammation often takes form of a chronic process and represents a damaging factor, exacerbating nervous tissue injury. Mechanisms that could switch immune response within CNS to physiological termination, referred to as resolution, are of high scientific and practical interest. In the current study, we have analyzed release of Resolvin D1 (RvD1) – a major lipid mediator of inflammation resolution derived upon enzymatic processing of docosahexaenoic acid (DHA) in mixed cultures of primary astrocytes within an in vitro model of neuroinflammation.

Methodology & Theoretical Orientation: Primary cultures of glial cells enriched in astrocytes were obtained from brains of neonatal Wistar rat pups by conventional procedures. Cells were stimulated with LPS for 4 and 24 hours. Cell lysates and cell free culture media were used to analyze COX-2 and TNFα expression as well as PGE2 release. RvD1 and DHA concentrations in cell-free culture media were analyzed by ELISA and HPLC/MS.

Conclusion & Significance: Glial cultures responded to LPS stimulation with upregulation of COX-2 and TNFα on both mRNA and protein levels and increase in DHA and PGE2 production. At the same time RvD1 was not detected in cell lysates or cell free culture media. The obtained results indicate that astrocytes are not directly involved into resolvin production upon LPS stimulation and have a unique role in the process of inflammatory response resolution within CNS.




Fig. 1. Astroglial cultures stimulated with LPS do not produce RevD1, important mediator of inflammatory response resolution.

Biography

Dmitryi V Chistyakov has his expertise in cell signaling pathways controlling inflammatory responses within the central nervous system. His scientific interests concern mechanisms that control innate immune response within nervous tissue on cellular level. Investigations within this field have brought him to the question about mRNA stability control during inflammatory response on the level of cells. These two processes – activation of innate immune response and post-transcriptional gene expression regulation turned out to be crucial for glioma development as well. Understanding their interaction during tumor development is one of the attractive directions of his research development.

chistyakof@gmail.com

Notes:


Hoda Azmy et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Benzimidazoles as epigenetic regulators of PRC2 protein complex with dual action as anti-tumor and nerve regenerators: Synthesis and molecular modeling Study


Hoda Azmy, Ghada S Hassan, Shahenda M El-Messery and **Ebrahim R Hamza**
Mansoura University, Egypt

Polycomb repressive complex 2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function correlates with certain malignancies and also correlates with the nerve regeneration process. EZH2 is the catalytic engine of the PRC2 complex responsible for the methylation process and is overexpressed in many malignancies thus represents a key candidate oncology target .It also plays a role in the regulation of action of EED subunit of PRC2 which in turn plays an important role in the nerve regeneration process after injury ,so Here in we try to regulate the expression of EZH2 using benzimidazole selective inhibitors resulting in a dual action helping in treatment of many malignancies and the nerve regeneration process. Some benzimidazole derivatives have been synthesized and structure elucidation was assured using NMR technique. 3-((1H-Benzo[d]imidazol-2-yl)amino)-2-(4-nitrophenyl)-1,3-thiazepan-4-one have bound to the target enzyme via Cys A663, Tyr A111, Tyr A111 and Tyr A661 aminoacid residue. Invitro studies are now in process hoping to treat specially the breast, prostate, liver and leukemia tumors and regenerate neuronal cells after application of stress media. In vivo studies will be operated soon.

Reference drug binding:



Using MOE, we found the ligands interation as follow:



2D ligand interaction of HE35d_14

3D interaction of HE35d_14 in the pocket

Biography

Shahenda M. El-Messery is associate professor of pharmaceutical organic chemistry at faculty of pharmacy, Mansoura University. Her research interest focuses on the design, synthesis, and evaluation of biologically active small molecules with getting the advantage of the molecular modeling modern techniques. She published scientific papers in peer reviewed journals.

hodaazmy95@yahoo.com
selmessery@gmail.com

Notes:

Silvia da Silva et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Aquatic physical activity alters plasmatic BDNF levels in individuals with Parkinson's disease

Silvia da Silva, Ivy Reichert Vital da Silva, João José Cunha, Pâmela Krause Peccin, Bernardo Vieira, Vera Lucia Widniczck Striebel, Simone Rizzo Nique da Silva Peralles, Daniela Pochmann and **Viviane Rostirola Elsner**
Centro Universitário Metodista-IPA, Brazil

Increasing evidence suggests that physical exercise have beneficial effects on the progression of Parkinson's disease (PD), alleviating the main symptoms and improving the performance in activities of daily living. Moreover, it was reported recently that different exercise protocols are able to increase the peripheral levels of brain-derived neurotrophic factor (BDNF), improving the health status of PD individuals. In this sense, aquatic physical exercise emerges as a proposal able of improving the quality of life of individuals with PD, since besides the physical activity by itself, the heated water eventually produces a feeling of relaxation, lightness and well-being during the performance of physical activities. However, the molecular mechanisms related to these beneficial outcomes are not elucidated. Thus, we investigated the short and long term effects of a program of aquatic physical activity on plasmatic BDNF levels of individuals with PD. The physical activity protocol was carried out during a month with two sessions per week (1 hour/session). Temporal BDNF levels were evaluated in plasma at different times: pre-intervention, immediately after the first session, 48 hours after the first session and one month after the first session. The data of all individuals analyzed together (n=9) demonstrated a significant decrease in BDNF levels 48 h after pre-intervention period ($p<0.05$). When data were divided by gender, we observed a significant decrease in BDNF levels evaluated at 48 h in comparison with the time immediately after the first session for both gender ($p<0.05$). In addition, our results showed that BDNF levels observed in female group (n=4) were significantly increased when compared to male group (n=5) at the time point of 48 h ($p<0.05$). No significant changes were observed on BDNF levels immediately after the first session (acute) or after one month (chronic). Our results demonstrated that the program of aquatic physical activity altered plasmatic BDNF levels in a time dependent and gender specific manner.

Biography

Silvia da Silva is currently pursuing her Post Graduation in the field of Biosciences and Rehabilitation at Centro Universitário Metodista-IPA, Porto Alegre, RS, Brazil.

silviads7911@gmail.com

Notes:

Yun Jung Choi, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Experiences of PTSD from traumatic incidents: A paradigm model from qualitative research


Yun Jung Choi
Red Cross College of Nursing, Chung-Ang University, Korea

Statement of the Problem: Koreans have experienced catastrophic disasters, which are continually growing for decades. Many people have died from shopping center breakdown, subway fire, ferry submerge, and so on. National psychological support system has been initiated for people who are affected from disaster, right after the subway fire disaster in Daegu in 2003. Even though many programs and educations had been provided for disaster psychological support over 10 years, the Sewol ferry accident in 2014 gave recognition that effective infrastructures for disaster psychological support were still deficient in Korea.

Methodology & Theoretical Orientation: This research attempted to explore mental health experiences from trauma to develop an evidence-based framework for preventing/early intervention of PTSD, depression, anxiety, or substance abuse of the population. A qualitative research design was used to examine the people's lived experiences.

Findings: A conceptual framework was constructed based on the paradigm of the trauma experience using 11 concepts (Figure 1).

Conclusion & Significance: Exploration of mental health problems associated with trauma provides evidence-based findings to help further mental health education, practice, administration, and research.



Biography

Yun-Jung Choi has her expertise in psychiatric/mental health nursing practice, research, and education. Her Hwa-Byung (Korean anger disorder) model based on Grounded theory creates new perspectives for understanding cultural care and improving healthcare. She also has contributed on disaster mental health care after years of experience in teaching and administration at the Red Cross College of Nursing. Recently, she is focusing on integrating her experiences of psychiatric/mental health nursing simulation using standardized patients, cultural mental health nursing, and psychological support for people with trauma.

yunjungchoi@cau.ac.kr


Notes:

Mohammad Sadegh Nikdad et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Glioblastoma multiforme: an advanced analysis of 153 patients and review of the literature

Mohammad Sadegh Nikdad[1], Farshid Farhan[1], Milad Shafizadeh[1], Atefeh Sadat Mirmohseni[1], Mohsen Afarideh[1], Shabnam Asadi Komeleh[1], Marzieh Lashkari[1], Morsaleh Ganji[1], Alireza Ghajar[1], Saeed Shafiei[1], Yalda Shafizadeh[2], Ali Kazemian[1] and **Hooshang Saberi[1]**
[1]Tehran University of Medical Sciences, Iran
[2]Emory University School of Medicine, USA

Glioblastoma multiforme (GBM) is an aggressive primary tumor with frequent recurrences that leaves patients with a short survival time and a low quality of life. The aim of this study was to review prognostic factors in patients with glioblastoma multiforme. The focus of this retrospective study was a group of 153 patients with supratentorial GBM tumors, who were admitted in a tertiary-care referral academic center from 2005 to 2013. Factors associated with survival and local recurrence were assessed using the hazard ratio (HR) function of Cox proportional hazards regression and neural network analysis. Of the 153 patients, 99 patients (64.7%) were male. The average age of patients was 55.69±15.10 years. The median overall survival (OS) and progression-free survival (PFS) were 14.0 and 7.10 months, respectively. In the multivariate analysis, age (HR=2.939, P<0.001), operative method (HR=7.416, P<0.001), temozolomide (TMZ, HR=11.723, P<0.001), lomustine (CCNU, HR= 8.139, P<0.001), occipital lobe involvement (HR=3.088, P<0.001) and Karnofsky Performance Status (KPS, HR=4.831, P<0.001) were shown to be significantly associated with a higher OS rate. Furthermore, higher KPS (HR=7.292, P<0.001), operative method (HR=0.493, P=0.005), the use of CCNU (HR=2.047, P=0.003) and resection vs. chemotherapy (HR=0.171, P<0.001) were the significant factors associated with local recurrence of tumor. Our findings suggest that the use of CCNU and TMZ, operative method and higher KPS readings are associated with both higher survival and lower local recurrence rates.



Biography

Mohammad Sadegh Nikdad is currently working as a Professor in the Department of Neurosurgery, Tehran University of Medical Sciences, Iran. His major area of interest includes Neurology, Neurosurgery, etc. He has published several original articles in the reputed and peer reviewed journals and also participated into several scientific meetings.

samannikdad@gmail.com

Notes:

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com









3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

e-Posters

CNS 2017

Ivan V Maksimovich, J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Early diagnosis of dementia stages in AD with cerebral tomography morphometry


Ivan V Maksimovich
Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky, Russia

Background: To early diagnose the severity of dementia in AD, we offer the Tomography Dementia Rating scale (TDR). Based on the morphometry of CT or MRI, the scale allows to determine the percentage of severity of atrophic changes in cerebral temporal lobes and to determine the severity of dementia due to the data obtained.

Methods: The research included 1078 patients: of which 93 patients aged 34-80 with AD at various stages were taken as Test Group, 985 patients aged 28-78 with various kinds of brain lesions with dementia but without AD (moderate and severe vascular dementia, Parkinson's atherosclerosis, Binswanger's disease, Parkinson's disease) were taken as Control Group. The examination plan included CDR assessment, MMSE, cerebral CT, MRI with subsequent temporal lobes atrophy degree calculation, scintigraphy (SG), rheoencephalography (REG), and cerebral MUGA.

Results: CT and MRI among all patients with AD revealed that brain characteristic objective morphological features were temporal lobes atrophic changes of 4-62% at various AD stages. These data made it possible to make a scale allowing certain atrophic changes determination at each AD stage: • Preclinical AD stage - TDR-0: temporal lobes atrophy with 4-8% tissue mass decrease. • Early AD stage - mild dementia - TDR-1: temporal lobes atrophy with 9-18% tissue mass decrease (corresponds to CDR-1). • Average AD stage - mild dementia - TDR-2: temporal lobes atrophy with 19-32% tissue mass decrease (corresponds to CDR-2). • Late AD stage - severe dementia - TDR–3: temporal lobes atrophy with 33-62% tissue mass decrease (corresponds to CDR-3). These atrophic changes are not observed among patients with other cerebral lesions.

Conclusions: The morphologically determined scale of AD-TDR stages is an effective method for objectively determining AD stage by means of widespread CT and MRI. At the same time, this scale allows to differentiate AD from other diseases that are accompanied by the development of cerebral neurodegenerative changes complicated by dementia and cognitive impairment. The scale is easily applicable to medical institutions allowing correct and objective AD stage determination in clinical practice.



Biography

Ivan V Maksimovich, MD, PhD is a member of ISTAART, ESC, EAPCI, WSO, ESO, and EPA. He is a Head Physician of Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky (Moscow, Russia) since 1993. One of the major problems the clinic deals with is the diagnosis and treatment of various brain lesions including Alzheimer's disease. Over the past 20 years, he has published over 200 scientific works on this subject.

carvasc@yandex.ru

Notes:

M Peicheva et al., J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Clinical description of familial cavernous malformations

M Peicheva[1], E Viteva[1], ATrenova[1], O Chaneva[1], Z Zahariev[1] and **E Tournier Lasserve[2]**
[1]Plovdiv Medical University, Bulgaria
[2]Lariboisière Hospital, France

Familial cerebral cavernous malformations is a rare inherited disease with a frequency of 1-5/10,000 in the general population. It is inherited in autosomal-dominant pattern through three genes - KRIT1, CCM2 and PDCD10, located respectively in 7q21.2, 7p13, 3q26.1 chromosomes. The disease is diagnosed mostly in Latin Americans. The manifestation is with multiple cavernomas in the head and spinal cord and rarely in retina and skin. Clinical symptoms are determined by localization of the lesions and their size. Most frequently occurring are epileptic seizures, focal neurological deficits, non-specific headache, cerebral haemorrhages, skin and retinal lesions. The disease occurs usually in adulthood and about 40% of cases are asymptomatic. The diagnosis is made with MRI images with multiple vascular malformations of cavernous characteristics and molecular-genetic analysis of the family members. We present a case of familial cerebral cavernous malformations in a father and a son of Armenian origin, diagnosed in the Clinic of Neurology of St. George University Hospital in Plovdiv. In the father, the disease debuted at a young age with epileptic seizures successfully treated with antiepileptic therapy. At age 76, there was abducens nerve palsy as well as a rapidly growing tumor formation in the neck. In the son, a 33-year-old man, the disease is manifested with epileptic generalized tonic-clonic seizures. The MRI performed in both show a number of brain cavernomas of different locations and sizes, some with a typical "popcorn-like" image, as well as deposition of hemoglobin degradation products and calcifications. An adrenal adenoma of the right adrenal gland and two cysts in the left kidney were also found in the older patient. Retinal lesions are not visualized in both. Genetic screening confirms the presence of mutation c.1061_1064dup in the exon 11 of the KRIT1 gene (transcript NM_194455). This is the first family in Bulgaria with familial cerebral cavernous malformations with a mutation in the KRIT1 gene and a typical clinical development.

Biography

M Peicheva is a Bulgarian Neurologist with experience in Vascular Disease. She works in Clinic of Neurology at St. George University Hospital in Plovdiv, Bulgaria. Her interests are connected with ultrasound examination and vascular abnormalities. She is a Volunteer Consultant at Raredis, a part of Bulgarian Institute for Rare Disease. Her last publications are about some rare syndromes in Bulgarian population.

mpeitcheva@yahoo.com

Notes:

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com









3rd International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

October 02-03, 2017 Vienna, Austria

Accepted Abstracts

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Spinal cord stimulation for chronic pain syndromes: Canadian experience

Ahmed A Al Jishi, Harsha Shanthana, Mauricio Forero, Valda Lopo, Frances Frazier, Mary Ann Van Doorn, Linda Gold, Jennifer Duley, Karen Carlino, Suzin Ilton and **Philp Chan**
McMaster University, Canada

Spinal cord stimulation (SCS) implantation has become popular in the last few decades. Currently, it is the gold standard therapeutic neuromodulation treatment that is being used in treating intractable chronic pain syndromes in patients who had failed medical treatment. The device has been successful in improving quality of life and decreasing narcotic intake. We wish to describe our experience with SCS implantation for the management of chronic pain syndromes and discuss our outcome through an outstanding and dedicated neuromodulation team.

dr_aljishi@yahoo.com

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Autism Spectrum Disorders: Neurological and Medical Comorbidities

Ann Neumeyer
Harvard Medical School, USA

The autism spectrum disorders (ASD) are a group of neurodevelopmental disorders characterized by impaired communication, social interaction and restricted and repetitive behaviors. In part, the impairment in communication results in more underdiagnosed comorbid disease. Neurological comorbidities including epilepsy, motor and sleep impairments will be discussed along with clinical findings in evaluation of the child with autism. Medical issues such as gastrointestinal disease, poor nutrition impact upon many systems including upon bone. Cross sectional and longitudinal studies have reported that boys with ASD have decreased bone mineral density. Children and adults with ASD also have higher odds of hip and other fractures based on a national emergency department database. The purpose of our study was to investigate the microarchitecture of bone and nutritional issues which could impact decreased bone development in boys with ASD. Methodology: observational longitudinal study of a cohort of approximately 20 boys with ASD and 20 age matched controls was followed for nutrition, areal bone mineral density and volumetric bone mineral density, which provides more information about fracture risk and had never been studied in a cohort of ASD boys. Findings: Boys with ASD had impaired microarchitectural parameters with reductions in bone strength estimates, calcium intake and IEF-1 responsiveness. Diet: Protein, calcium and phosphorus intake were lower in ASD than TDC and were associated positively with BMD measures. Conclusion and Significance: Boys with ASD were less physically active and protein, calcium and phosphorus intake were lower in ASD than control peers and are associated positively with bone density. The impairments in microarchitectural parameters may result from lower physical activity, calcium intake and IGF-1 responsiveness. Our study suggests that encouraging diets higher in fortified dairy and animal protein, as well as increased high-level exercise may improve bone health. Identifying neurological and medical comorbidities has important implications for better care of the child with autism spectrum disorders.

aneumeyer@mgh.harvard.edu

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Plastin3 as a therapeutic Target in Spinal Muscular Atrophy

Aziza Al-Rafiah
King Abdul Aziza University, Saudi Arabia

Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease caused by mutations in the survival motor neuron 1 gene (SMN1). SMN1 and SMN2 are nearly identical genes producing the survival of motor neuron (SMN) protein. SMN protein plays a crucial role in mRNA splicing and β-actin mRNA transport along the axons. In SMA the mutation leads to the loss of SMN1, which cannot be fully compensated by the SMN2 gene, which predominantly produces a truncated protein. The loss or reduction of SMN protein leads to motor axonal defects and motor neuron cell death. There are currently no treatments available but therapies have focused on increasing SMN through replacing SMN1 or increasing full length SMN from SMN2. The actin-binding protein Plastin 3 (PLS3) has been reported as a modifier for SMA, making it a potential therapeutic target. Recently, it was shown that the overexpression of the PLS3 gene improved axonal outgrowth in SMN- deficient motor neurons of SMA Zebrafish and cultured motor neurons from mouse embryos. Gene therapy using viral vectors was carried out in vitro and in vivo to assess whether the overexpression of PLS3 could rescue neuronal loss in SMA and be developed as a therapy. The SMNΔ7 mouse model produces low levels of SMN, modelling severe SMA disease with an average lifespan of 12 days and loss of motor neurons. This study has established that the SMNΔ7 mice have little or no detectable PLS3 from birth, making it a good model for developing PLS3 gene therapy. Lentiviral vectors were able to upregulate PLS3 expression in different cell lines. Transduction of NSC34 cells with LV-PLS3 vector led to a five-fold increase in expression of PLS3 compared to controls. In smn-deficient MNs, expression of PLS3 restored axonal length and showed a strong neuroprotective effect. Pre-clinical in vivo proof-of-concept studies using adeno-associated virus serotype 9 (AAV9) encoding PLS3 in SMNΔ7 mice showed high transduction efficiency and overexpression of PLS3 specifically targeted to neurons in the central nervous system (CNS). This led to a small but significant increase of lifespan by 54%. However, PLS3 was not able to prevent disease onset. Although there was no improvement of phenotype, this study has demonstrated the potential use of PLS3 as a target for gene therapy, possibly in conjunction with other modulators of disease.

aalrafiah@kau.edu.sa

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

High resolution, non-invasive multimode optical imaging: A proposed diagnostic and assessment tool in Alzheimer's Disease

Daniel L Farkas
University of Southern California and the Brain Window, Inc., USA

Statement of the Problem: Alzheimer's Disease (AD) is a major unmet health challenge characterized by (a) fast increasing incidence and costs; (b) very late diagnosis.

Methodology: Our group has recently [1] introduced optical imaging in the retina as a non-invasive method for mapping the occurrence, size and location of beta amyloid plaques, the primary pathology in AD. We have shown that using the fluorescence of curcumin, which attaches specifically to these plaques, we could quantitate the features of these plaques, including in vivo, and even document their reduction by immune treatments. These preclinical studies were also extended to the clinical domain, by using archival human eyes from patients with known levels of AD, as assessed both by brain histopathology and cognitive impairment (prior to death). We present a method for extending such studies to living patients, still using the retina as the window to the brain and plaques as indicators, but without the use of an extrinsic biomarker such as curcumin (as in [1]). This raises the level of experimental difficulty, thus requiring new technologies that we invented and/or perfected.

Findings: We designed a multimode optical imaging instrument, essentially a new type of confocal scanning laser ophthalmoscope, with some (needed) performance advantages over current commercial offerings. Our system consists of the following elements, all proprietary, and patent-protected: (a) A highly versatile light source: pulsed, 400-1400 nm, with ~1 nm resolution; (b) A new galvanometric method of scanning, with synthesized pivot point, not requiring a custom coupling lens; (c) Spectral analysis of imaging data, including hyperspectral image segmentation and elimination of background; (d) A more sensitive method of detecting light, via parametric

Conclusion & Significance: This new instrument achieves significant improvements in all of the following: spatial resolution, imaging depth, imaging angle in the retina (and thus spatial coverage), sensitivity and specificity. It will be used to image, fast and non-invasively, amyloid plaques in the retina, and any other retinal features of interest. We envisage that this instrument and the approach it enables should be used in AD drug/treatment trials, as it allows the repeatable, non-invasive and quantitative imaging of amyloid plaques (via both their autofluorescence and scattering), and of their relationships with important structures in the eye, such as blood vessels.

dlfarkas@gmail.com

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Clinical Utility of Brainstem Auditory Evoked Potentials (BAEP) as Diagnostic and Prognostic Neurophysiological Markers in Patients with Concussion

Diana Tsakova
Military Medical Academy, Bulgaria

Introduction: The standard approach in patients with concussion includes neurological/neurosurgical examination and neuroimaging (CT/MRI). Despite the normal results from these examinations, some complaints often persist for different period of time and disturb their quality of life. The aim of this study is to investigate changes of BAEP as diagnostic and prognostic neurophysiological markers in patients with concussion.

Method: Twenty-three patients (age range 18-44) with concussion were included in the study. Control group includes 35 subjects. In all 23 patients CT/MRI was conducted to exclude more severe TBI. In all patients were conducted BAEP in the first month after injury. In 10 patients a BAEP follow-up was carried out on the 3rd or 6th month after the trauma.

Results: The abnormal rate of BAEP for patients with concussion was 86.95%, indicating dysfunction of the brainstem in those patients. There was a statistically significant difference between the abnormal rate of patients and that of healthy persons. In the first month after the trauma 20 patients had abnormalities: delayed peak latencies, abnormal prolongation of interpeak intervals, interaural differences. 16 of them had more than one type of abnormalities. Three patients had normal BAEP. In control BAEP in 10 patients the abnormalities persist. (Fig.1).

Conclusions:

- BAEP can be applied as a diagnostic method in patients with concussion for objectifying some functional disturbances in cases of normal CT/MRI.
- Conducting control BAEP (3, 6 monts) has an important role in monitoring the dynamics of pathological process.
- Persistent abnormalities in BAEP can be used as diagnostic and prognostic neurophysiological markers for establishment of incomplete recovery – for temporary disabilities and legal claims for compensation.
- In patients with MTBI with normal CT/MRI it is recommended expansion of the diagnostic algorithm with BAEP as objective, sensitive and highly informative indicator of brainstem disturbances.

di_nerves@mail.bg

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Chronic Brain Glucose Deficits Modulates Neuropathology and Dementia: Implication For Alzheimer's Disease

Domenico Praticò
Temple University Lewis Katz School of Medicine, USA

In recent years, growing experimental evidence has suggested a direct association between altered glucose metabolism, brain function and neurodegeneration. Together with human studies, the investigations using experimental models have all convened on a common final point: dysregulated brain glucose levels and impaired energy metabolism in the brain are not only a clinical feature of Alzheimer's disease (AD) but also important contributors to its pathogenesis. Some evidence suggested that brain glucose deficits can influence amyloid beta levels in vivo but no data are available on the effect that this condition might have the development of tau neurofibrillary tangles and cognitive functions, the other two most important faetures of AD pathophysiology. In this paper we investigated the effect of chronic brain glucose deficits and energy dysregulation on memory and learning, synaptic function as well as the development of tau neuropathology in a model of tauopathy. Compared with controls, a condition of glucose deprivation and chronic brain energy deficiency resulted in significant memory deficits, impaired synaptic function, increased tau phosphorylation and neuronal cell death via apoptosis. Our studies demonstrate that reduced glucose availability in the central nervous system promotes directly the development of memory impairments, tau neuropathology, synaptic dysfunction, and neuronal cell death. Since restoring brain glucose levels and metabolism could afford the opportunity to positively influence the entire AD phenotype, it should be considered as viable therapeutic approach for this disease and related dementias.

praticod@temple.edu

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Cucurbitacin B mitigates experimental autoimmune encephalomyelitis by inhibition of IL-17/IL-23 immune axis

Nima Sanadgol
University of Zabol, Iran

Pharmacological approaches to inhibit brain acute inflammation may represent important strategies for the control of autoimmune diseases. Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and autoimmune disease of the central nervous system (CNS). Cucurbitacin B (CuB), an oxygenated tetracyclic triterpenoid compound extracted from Cucurbitaceae plant species, is a bioactive agent by disruption of microtubule polymerization and inhibition of JAK/STAT signaling. However, there has been little information about impact of CuB on MS treatment. In this research, for the first time we examine effects of CuB (specific STAT3 blocker), in experimental autoimmune encephalomyelitis (EAE) mouse model of MS. EAE was induced by subcutaneous immunization of MOG35-55 in 8-week-old C57BL/6 mice. CuB was administered at different doses (0.25, 0.5 and 1 mg/kg body weight/day/i.p) from the first day of the experiment. Inflammatory responses were examined using qRT-PCR, western blot and immunohistochemistry (IHC) analysis of specific markers such as p-STAT3, IL-17A, IL-23A, CD11b and CD45. CuB reduced STAT3 activation, leukocyte trafficking, and also IL-17/IL-23 immune axis in this model. Treated mice with lower doses of CuB exhibited a considerable depletion in the EAE clinical score which correlated with decreased expression of IL-17, IL-23 and infiltration of CD11b+ and CD45+ cells into the CNS. Our in vivo results suggest that STAT3 inhibition by CuB will be an effective and new approach for the treatment of neuro-inflammatory disease such as MS.

Sanadgol.n@gmail.com

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Effectiveness of an alternate approach durotomy in decompressive craniectomy in severe TBI

Venkataramana Pamidimukkala, Deepak S Mandwe, Harshavardhan Batsala, Sivaramakrishna Kondapalli, Kuchela Babu V and **Mohana Rao A**
MKCG Medical College, India

Introduction: Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Decompressive craniectomy is an emergency neurosurgical procedure in patients who have sustained TBI resulting in raised ICP.

Objective: To study surgical methods and techniques to improve results following decompressive craniectomy. Patients and Methods: We have treated 3177 TBI patients from January 2009 to December 2016. Decompressive craniectomy (DC) was done in 468 patients while rest were treated conservatively. The protocol followed was neuro ICU care, radiological and neurological monitoring. DC was done if there was neurological deterioration or midline shift in the CT scan. A speedy craniectomy was done with a 'lazy question mark' skin incision. The flap included the temporalis muscle, followed by a 12 to 16 cm wide craniectomy. The dura was first opened in the frontal region and 'pizza slicing' of dura was done. Additional cuts were made over the draining veins close to the saggital sinus in the form of vascular tunnels. A synthetic dural graft was shaped and positioned but not sutured.The temporal muscle was not sutured. Single layered skin closure was done followed by the application of a loose bandage.

Conclusion : Pizza slicing of dural opening in contrast to conventional sinus based or skull base, based flap prevents compression on the viens which are already compromised due to oedema. Post traumatic malignant oedema and venous infarcts were greatly avoided. Keeping the dural patch loosely and single layer closure prevents damping of the brain pulsations. Wound complications or CSF leaks greatly decreased.

neuroramana@gmail.com

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Combined Effect of Baclofen and Acamprosate in Experimental Models of Peripheral Neuropathic Pain in Wistar rats

Varun Vikas Vij
Dayanand Medical College and Hospital, India

Neuropathic pain (NP) is defined as pain associated with damage or permanent alteration of the peripheral or central nervous system. Current drug treatment for the management of neuropathic pain associated with various adverse effects. The present study was designed to investigate the combined effect of acamprosate and baclofen in experimental model of peripheral Neuropathic pain in wistar rats. Material and Methods: Neuropathic pain was induced by chronic constriction injured (cci) of sciatic nerve in rats. A camprosate (100 and 200 mg/kg p.o) and baclofen (10 and 20 mg/kg p.o) was given in different groups for 14 days starting on 7th day post sciatic nerve ligation. Further combination of acamprosate(100 mg/kg p.o) and baclofen (10 mg/kg p.o) was also given to one group. On 1th, 3rd, 7th, 14thand 21stday behavioral parameters like mechanical allodynia and thermal hyperalgesia were assessed. Then animals were sacrificed on 22nd day and biochemical parameters (gsh, lpo, catalase, nitrite, sod) were assessed. Results: ligation of sciatic nerve significantly induced mechanical allodynia and thermal hyperalgesia with increase in oxidative stress (increase in lpo and nitrite) and decline of anti-oxidant enzyme levels (catalase, sod, gsh) in sciatic nerve homogenate. A camprosate (100 and 200 mg/kg p.o) and baclofen (10and 20 mg/kg p.o) attenuated all the behavioural and biochemical parameters alone and/or combination.

Varunkumar1982dec@gmail.com

J Neurol Disord 2017, 5:5(Suppl)
DOI: 10.4172/2329-6895-C1-024

Imaging of serotonin synthesis and brain serotonergic receptors and their relation to affective disorders

Mirko Diksic
McGill University, Canada

The study of regional serotonin synthesis in humans by imaging could enable researchers to obtain a better understanding of affective disorders and to develop better therapies.

Objective: To perform imaging of regional brain serotonin (5-HT) synthesis with labelled α-methyl-L-tryptophan [α-MTrp] in the normal and affected brain, as well as in the animal models of depression.

Methods: Studies were performed on laboratory animals using two different rat models of depression, where the synthesis was measured by autoradiography, and a 14C and 3H-labelled tracer. Positron emission tomography (PET) with a 11C-labelled tracer was used in the human studies, on both normal subjects and on patients with various brain disorders (e.g., epilepsy, depression, obsessive compulsive disorder, borderline personality disorder, and those suffering from migraines). The patients met the DSM-IV criteria for depression or bipolar disorder (BPD), a disorder characterized by affective ability and impulsive aggressive behavior.

Results: The experiments in rats have shown that 5-HT synthesis is elevated in bulbectomized rats (using a model of agitated depression) and reduced in the Flinders Sensitive Line rats (using a model of retarded depression), and that antidepressants (e.g., citalopram, buspirone) have the effect of returning the synthesis to the level of the control rats without having a significant effect on plasma Trp concentration. The drugs have different effects following chronic and acute administration. The data suggest that 5-HT synthesis is differently controlled in the terminal areas than in the cell bodies. The results indicate that in healthy women, when compared to healthy men, serotonin synthesis is significantly lower in the right parietal lobe, bilateral middle frontal gyri, and bilateral parieto-occipital lobe. When comparing synthesis in the male BPD subjects to the male controls, we found a lower synthesis level in the anterior cingulate and left temporal lobe of the male BPD subjects, while the synthesis in the BPD subjects was higher in the posterior cingulated.

Conclusion: In depressed patients, we found a significant bilateral decrease in the anterior cingulate (ACC) (females), in the left ACC (males), and in the left mesial cortex (both gender). In addition, we have shown that antidepressants have region specific influence on 5-HT synthesis. In rat models of depression was shown that antidepressant produces changes in 5-HT synthesis and some 5-HT receptor sites. Some of these correlate with behavioural changes. The evaluation and imaging of regional synthesis, using α-MTrp as a tracer, is an excellent methodology for studying changes in brain 5-HT synthesis and the regional effects of drugs, in normal patients and in those with affective disorders which can help id discovery new drugs and new treatment modalities.

mirko.diksic@mcgill.ca

INDEX

Alessandro M Morelli	31
Antonio Scilimati	19
Brahim Gargouri	24
Debabrata Mukhopadhyay	23
Delich O B	35
Delich O B	38
Dionisio Figueiredo Lopes	18
Dmitryi V Chistyakov	40
Dmitryi V Chistyakov	41
Hanan Sheikh Ibrahim	20
Hoda Azmy	42
Ivan V Maksimovich	48
Khin Bo Maung	30
M Peicheva	49
Melnyk Nataliia O	26
Mohammad Sadegh Nikdad	45
Seyed Behnamedin Jameie	27
Seyed Behnamedin Jameie	36
Silvia da Silva	43
Toshio Obata	39
Yun Jung Choi	44

Meet Inspiring Speakers and Experts at our 3000+ Global Events with 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology, Business and 700+ Open Access Journals

Conferences | Publishing | Global Networking | Research | Business

Exhibitions | Collaborations | Careers | International Memberships | Advertisements & Promotions

Conferences By Continent

USA & Americas

USA | Brazil | Canada | Mexico

Asia-Pacific

Australia | China | India | Japan | Malaysia | New Zealand | Philippines | Singapore | South Korea

Europe & Middle East

Austria | Denmark | Finland | France | Germany | Italy | Netherlands | Norway | Poland | South Africa | Spain | Switzerland | Turkey | UAE | UK | Ukraine

Medical & Clinical Journals and Conferences

- Alternative Healthcare
- Cardiology
- Dentistry
- Dermatology
- Diabetes & Endocrinology
- Gastroenterology
- Healthcare Management
- Hematology
- Infectious Diseases
- Medical Ethics
- Health Policies
- Neuroscience
- Nephrology
- Nursing
- Obesity
- Oncology & Cancer
- Ophthalmology
- Palliativecare
- Pathology
- Pediatrics
- Physical Therapy Rehabilitation
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Vaccines
- Reproductive Medicine &
- Women Healthcare

Journals and Conferences by Subject

- Agri, Food & Aqua
- Biochemistry
- Business & Management
- Chemical Engineering
- Chemistry
- EEE & Engineering
- Environmental Science
- Genetics & Molecular Biology
- Geology & Earth Science
- Immunology
- Materials Science
- Microbiology
- Nanotechnology
- Nutrition
- Oncology & Cancer
- Petroleum
- Pharma Marketing & Industry
- Pharmaceutical Sciences
- Physics
- Veterinary

Contact us

Conference Series - America
One Commerce Center-1201, Orange St. #600
Wilmington, Zip 19899, Delaware, USA
P: +1-702-508-5200, F: +1-650-618-1417
E: america@conferenceseries.com

Conference Series - UK
Kemp House, 152 City Road
London EC1V 2NX, UK
Toll Free: +1-800-014-8923
E: europe@conferenceseries.com

Conference Series - Asia Pacific
6th Floor, North Block, Divyasree Building, Raidurg, Hyderabad
Telangana, INDIA-500032 P: +91-40-33432300
E: asia@conferenceseries.com

Toll Free

Australia - 1-800-651-097 | **France** - 0805-080048 | **Hyderabad** - 91-40-71279012

Hyderabad - 91-40-71279013 | **UK** - 0-800-014-8923

Los Angeles Downtown - 1-213-233-9462 | **USA/Canada** - 1-888-843-8169

Upcoming Neuroscience Conferences

10th International Conference on
Vascular Dementia
February 22-23, 2018 Paris, France
vasculardementia.conferenceseries.com

21st World Congress on
Neurology and Therapeutics
March 15-17, 2018 London, UK
neurologyconference.com

25th World Congress on
Neurology & Neuroscience
June 14-16, 2018 Amsterdam, Netherlands
neuroscience.neurologyconference.com

11th International Conference on
Alzheimer's Disease & Dementia
March 29-31, 2018 Vienna, Austria
alzheimers-dementia.neurologyconference.com

26th European Neurology Congress
August 06-08, 2018 Madrid, Spain
www.neurologyconference.com/europe

Bookmark your dates

4th International Conference on

CENTRAL NERVOUS SYSTEM DISORDERS AND THERAPEUTICS

November 12-14, 2018 | Edinburgh, Scotland

E-mail: cns@neuroconferences.com; cns@neuroconferences.org
Website: cns.conferenceseries.com